FR2949674A1 - Cosmetic use of antagonistic agent of neuropeptide Y comprising e.g. extract comprising e.g. extracts obtained from Cynara scolymus in composition to improve appearance of lips by increasing volume and/or natural color of lips - Google Patents

Abstract

Cosmetic use of at least one antagonistic agent of the neuropeptide Y (NPY) (I) comprising peptides or nonpeptide chemical molecules or an extract comprising e.g. extracts obtained by extraction of sponge Orina sp., Gray sp.or Gellius sp., extracts from fermentations of Aspergillus strains, and extracts obtained from Cynara scolymus, in a composition containing a medium, to improve the appearance of lips by increasing the volume and/or the natural color of lips, is claimed. Cosmetic use of at least one antagonistic agent of the neuropeptide Y (NPY) (I) comprising peptides or nonpeptide chemical molecules or an extract comprising extracts obtained by extraction of sponge Orina sp., Gray sp.or Gellius sp., extracts from fermentations of Aspergillus strains, extracts obtained from fermentation of Actinomycetaceae strains and extracts obtained from Cynara scolymus, in a composition containing a medium, to improve the appearance of lips by increasing the volume and/or the natural color of lips, is claimed. Independent claims are included for: (1) cosmetic process to plump up and/or providing natural color to lips comprising (a) applying a composition comprising at least one antagonistic agent of neuropeptide Y to the lips; and (2) set or kit for lip care comprising: (aa) a composition comprising a lipstick, liquid lip gloss, lip paste, lip pencil, lip balm or lip varnish; and (bb) a second composition comprising as active agent, at least one antagonist of neuropeptide Y. ACTIVITY : Dermatological; Vasotropic; Vasodilator. MECHANISM OF ACTION : Neuropeptide Y (NPY) antagonist.

Description

The field of the invention relates to the care and beautification of the lips.

By lip, it will be understood, according to the present invention, the red lip, and more particularly the vermilion.

The red lip is the free edge of the lip which includes an internal mucous portion, or wet lip, in continuity with the oral mucosa and an external, visible, semi-mucous or dry lip called vermilion. The posterior limit of vermilion is defined by the point of contact when the mouth is closed. Its outline consists of the mucocutaneous junction line. Vermilion is red in fair-skinned and pigmented subjects in colored subjects. The red lips are a semi-mucous membrane, that is to say a mucous membrane covered with a very fine epithelium of a few layers of cells. They do not benefit from the protection of the epidermis and the stratum corneum like the other parts of the face.

However, like other parts of the face, the lips are constantly exposed to external aggressions (cold, hot, wind, dry air), they are also a constantly moving area and therefore subject to mechanical stress (speech, expression, food .. .) and wet (saliva, drink ...).

One of the aesthetic consequences, especially with rage, is a lack of firmness, a lack of volume and the formation of fine lines on the lips. Thus, it is useful to identify new active ingredients which improve the appearance of the lips and in particular increase the volume of the thin lips and / or smooth the lips, these new agents being to be applied alone to give a very natural finish (product of care in particular immediate anti-aging effect) or in the form of gloss, in / or in addition to the usual lipstick.

By natural make-up of the lips is meant, according to the invention, a means for improving the appearance of the lips and in particular for coloring and / or repulping the lips naturally, as opposed to conventional lip makeup 35 which implements makeup agents such as dyes, specific pigments or reflective particles, capable of conferring an optical effect of coloration and / or volume (pulping effect) of the lips. Naturally coloring means, according to the invention, to increase the naturally rosy color of the lips. According to the invention, plumping is understood to mean increasing the size and / or the volume and / or the thickness of the lips and / or remodeling and / or smoothing them and / or giving them a more inflated or fleshy appearance.

Fine lips, especially in women, can be considered unsightly. To increase the thickness of the lips, women use techniques such as cosmetic surgery, injections or tattooing, and the use of these techniques tends to become widespread including among women with normal lips, eager to fleshy or luscious lips. However these techniques are expensive, can give for some an irreversible result (ex: cosmetic surgery, tattoo), or be generating for others of side effects of the type infection or allergy (ex: injection of collagen, tattoo ...) . No. 5,571,794 discloses the use of mixtures of agents selected from (i) local vasodilators such as betaadrenergic receptor blocking agents or muscarinic acetylcholine receptor activating agents; (ii) local irritants; and (iii) homeopathic dose elements; to increase the size of the lips. More recently, WO03 / 072039 discloses compositions containing a polymer of 7 to 15 units of L-Arginine for increasing the size of keratin materials such as skin, hair, lips and gums.

Neuropeptide Y (NPY) is a peptide of 36 amino acids highly expressed in the central nervous system. This peptide is known to have many physiological roles. It is described, for example, as having an analgesic effect, on food intake, circadian rhythm control, sexual function, anxiety, vascular resistance, substance P release in neurogenic inflammation, and on the control of immune processes.

The effects of NPY can be variable from one organ to another. NPY is described, for example, as a potent vasoconstrictor in the heart and brain but as a vasodilator in the skin (Wallengren et al., J. Investig.Dermatol, Symp., Proc., 1997, 2 (1) 49 -55). The action of this compound on certain organs is still unknown or uncertain. WO 2004/075867 discloses a composition having a cutaneous anti-inflammatory effect, comprising a plant extract which makes it possible in particular to fight against the vasodilator effects of NPY, salted out during inflammation,

The effects of NPY can be as diametrically opposed in the human body or in the same organ. Although the effects of NPY have been demonstrated on the cutaneous vascularization, the effects of this neuropeptide on cutaneous microcirculation are not yet well established. These effects may be vasodilators or vasoconstrictors. They would depend on the anatomical site and the depth where the microvessels are located (Hodges GJ, Jackson DN, Mattar L, JM Johnson, Shoemaker JK, Am J Physiol Regul Integr. Comp Physiol 2009 Sep; 297 (3): R546-55).

The specificity of microcirculation at the level of the lips has not yet been studied.

In FR 2895253, the presence of NPY in the lips is highlighted. NPY agonist compounds have thus been proposed for plumping and / or recoloring the lips naturally.

Unexpectedly, the Applicant has discovered the vasoconstrictor effects of NPY on the vessels of the lips. From this discovery, the Applicant has proposed to act on the appearance of the lips by inhibiting the vasoconstrictive effects of NPY.

Thus, the invention relates to the cosmetic use of an effective amount of at least one neuropeptide Y (NPY) antagonist agent, in a composition containing a physiologically acceptable medium, to improve the appearance of the lips by increasing the volume and / or the natural color of the lips. This increase in the volume and / or color of the lips is explained by the vasodilatation of the vessels of the lips.

By effective amount is meant a quantity allowing said agent to produce its effect.

Preferably, this invention relates to the cosmetic use of an effective amount of at least one neuropeptide Y (NPY) antagonist agent, to increase the size and / or the thickness of the lips and / or remodel them and / or smooth them and / or give them a more swollen or fleshy appearance and / or to increase the naturally rosy color of the lips.

Because of its activities, the NPY antagonist compound may be incorporated into any composition for topical application to the lips.

Thus, according to another of its objects, the invention relates to compositions comprising, in a physiologically acceptable medium, at least one NPY antagonist compound, characterized in that it is in the form of a lipstick, a liquid gloss, a lipstick, a lip contour pencil, a lip balm, or a nail polish. The compositions may have as their destination the protection, repair, care or treatment of the lips. It may also be makeup composition that may, for example, both to treat and hide skin disorders of the lips. Another subject of the invention relates to a cosmetic process for improving the appearance of the lips and more particularly to plumping and / or coloring the lips naturally, comprising applying to the lips a composition comprising at least one antagonist of neuropeptide Y.

Preferably said application to the lips of the composition comprising at least one neuropeptide Y antagonist, will be carried out before the application, on said lips, of a composition not comprising a neuropeptide Y antagonist, this composition being chosen from a lipstick, liquid gloss, lipstick, lip contour pencil, lip balm or lip polish.

Another subject of the invention relates to a set or kit for the care of the lips comprising: a) a composition chosen from a lipstick, a liquid gloss, a lipstick, a lip contour pencil, a lip balm, lips or a lip varnish and, b) a second composition comprising, as active agent, at least one neuropeptide Y antagonist.

Said composition will preferably be a liquid gloss.

The NPY antagonist agents are either chemical molecules, peptidic or nonpeptide, or any type of extract characterized by a type of antagonist activity of NPY, preferentially type Y1.

Preferably, said agent will have a specific affinity for the Y1 receptor of NPY. NPY antagonist agents have been described for uses other than that of the present invention.

EP 1093803, EP 0838217 and FR 2865652 describe cosmetic compositions containing an NPY antagonist compound. These compositions are described as regulators of lipolysis or lipogenesis, the adipocytes of which are responsible for the skin without interfering with the natural functions thereof.

In FR 2895239, it is disclosed that NPY antagonists may be used for the care of weakened, sensitive or damaged lips and that this makes it possible in particular to treat the sensations of yeast, that is to say the sensations related to a decrease or an exaggeration of the sensibility. The bleaching effect of these NPY antagonist compounds is also described to reduce the redness of the lips and restore their uniform color.

These NPY antagonist agents can be identified on the basis of receptor binding to the Y1 receptor of NPY, for example by the methods described by Fuhlendorf J. et al (PNAS-USA, 1990, 87, p182) or by Wieland et al. . (J. Pharmacol Exp Ther, 1995, 275, 143-149). The antagonistic nature of the NPY of the compounds can also be demonstrated by studies on isolated organs and more particularly in the "vas deferens" rat model, in particular according to the protocol described in Regulatory Peptides 1986, 13, 307-318.

As an example of NPY antagonist agents, mention may be made of all of the NPY antagonistic compounds or extracts listed in EP 0 838 217: 1. The compounds of formula (I) ## STR1 ## In which - Art represents naphthyl, phenyl, quinolyl or isoquinolyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy, hydroxyl or (C1-C4) dialkylamino; Ar 2 represents phenyl or thienyl, optionally substituted with Cl, F, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or hydroxyl; R1, R2 and R'2 represent, independently of one another, hydrogen, (C1-C4) alkyl or R1 represents nothing and N is bonded to Ar2 and, optionally, R2 and R'2 form a double bond, or R1 or R2 is bonded to Ar2 and represents (C1-C3) alkylene; R3 and R4, which are identical or different, represent hydrogen, (C1-C4) alkyl or form, with the nitrogen atom to which they are bonded, a (C5-C7) saturated heterocycle chosen from pyrrolidine, piperidine and hexahydroazepine; - Z1 represents (C1-C12) alkylene interrupted or optionally substituted with (C5-C7) cycloalkyl or phenyl; Q1 represents methyl, amino, (C1-C4) alkoxycarbonylamino, (C1-C4) alkylamino, di (C1-C4) alkylamino, pyrrolidinyl, piperidino, morpholino, piperazinyl, (C1-C4) alkyl-4-piperazinyl, amidino (C1-C4) alkylamidino, guanidino, (C1-C4) alkylguanidino, pyridyl, imidazolyl, pyrimidinyl, indolyl, hydroxy, (C1-C4) alkoxy, (C2-C8) alkoxycarbonyl, N- [amino (C1-C4) alkyl] -N - [(C1-C4) alkyl] amino, carbamoyl or phenyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy or hydroxyl; Q 2 represents hydrogen or (C 1 -C 4) alkyl; NùQ3 • C NùZ, ùQ, '(I) Q2 Are R4 - Q3 represents hydrogen or (C1-C4) alkyl or Q1 and Q3 are bonded to form a heterocycle and together represent (C2-C3) alkylene while Z1 does not. represents nothing, in the form of pure enantiomers or their mixtures in any proportions, as well as their addition salts with acids, prepared according to EP 0 614 911.

II - The analogues of raloxifene and in particular a) The compounds of formula (II) (H) in which: - A ° is -O-, -S (O) m-, -N (R ° 6) -, - ( CH2) 2- or -CH = CH-; - R6 is hydrogen or (C1-C6) alkyl, and m is 0, 1, or 2; X ° is a bond or a (C1-C4) alkylene; R 2 is a group of formula wherein R 4 and R 5 are independently (C 1 -C 6) alkyl or together with the nitrogen atom to which they are attached form a heterocyclic group chosen from hexamethyleneiminyl, piperazino, heptamethyleneiminyl, 4-methylpiperidinyl, imidazolinyl, piperidinyl, pyrrolidinyl or morpholinyl; - R ° is a hydroxy, a halogen, a hydrogen, a (C 3 -C 8) cycloalkyl, a (C 2 -C 7) alkanoyloxy, a (C 1 -C 6) alkoxy, or a phenyl, said phenyl being optionally substituted by one, two or three substituents selected from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, nitro, chlorine, fluorine, trifluoromethyl, -OSO2- (C1-C10) alkyl or -OC (O) -NH-R ° - R 1 is hydroxy, halogen, hydrogen, (C 3 -C 8) cycloalkyl, (C 2 -C 7) alkanoyloxy, (C 1 -C 6) alkoxy, or phenyl, said phenyl may be optionally substituted with one, two or three substituents chosen from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, nitro, chlorine, fluorine, trifluoromethyl, -OSO2- (C1-C10) alkyl or -OC (O) -NH-R3; wherein each R3 is independently (C1-C6) alkyl, (C3-C8) cycloalkyl, unsubstituted or substituted phenyl wherein the substituent is halogen, (C1-C6) alkyl or (C1-C6) alkoxy; with the limitation that when X ° is a bond and A ° is -S-, then R ° and R ° 1 are not both selected from the group consisting of hydroxy, methoxy and (C2-C7) alkanoyloxy; as well as its salts or solvates, preparable according to WO 96/12489 and preferably a compound chosen from: 3- (4-methoxyphenyl) -4- [4- (2-pyrrolidin-1-ylethoxy) benzoyl] -1,2-dihydronaphthalene 3-phenyl-4- [4- (2-pyrrolidin-1-ylethoxy) benzoyl] -7-methoxy-1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (piperidine) 1-yl) ethoxy] benzoyl] -1-, 2-dihydronaphthalene, 3- (4-hydroxyphenyl) -4- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene 3- (4-methoxyphenyl) -4- [4- [2- (hexamethyleniminimin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene, 6) 3- (4-methoxyphenyl) -4- [4- 2- (Piperidin-1-yl) ethoxy] benzoyl] -1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (piperidin-1-yl) ethoxy] benzoyl] -7- methoxy-1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- [4- [2- (N-methyl-1-pyrrolidinium) ethoxy] benzoyl] -1,2-dihydronaphthalene, 3- (4-methoxyphenyl) ) 4- [4- (2-Dimethylaminoethoxy) benzyl] -1,2-dihydronaphthalene, 3- (4-methoxyphenyl) -4- (4-diethylaminoethoxybenzoyl) 1) -1,2-Dihydronaphthalene, 3- (4-methoxyphenyl) -4- (4-diisopropylaminoethoxybenzoyl) -1,2-dihydronaphthalene, 2- (4-hydroxyphenyl) -3- [4- [2- (hexamethyleneimino) -1- 1-yl) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2- (piperidin-1-yl) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4- hydroxyphenyl) -3- [4- [2-pyrrolidin-1-yl) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-diethylamino) ethoxy) ] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-diisopropylamino) ethoxy] benzoyl] -6-hydroxybenzofuran, 2- (4-hydroxyphenyl) -3- [ 4- [2- (N, N-dimethylamino) ethoxy] benzoyl] -6-hydroxybenzofuran, 1-ethyl-2- (4-methoxyphenyl) -3- [4- [2- (p-perid-1-yl) -ethoxy) -ethoxybenzofuran; ] benzoyl] -6-hydroxyindole, 2- (4-methoxyphenyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (Piperidin-1-yl) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] 6-metho xybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (N, N -diethylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (4-methoxyphenyl) -3- [4- [2- (N, N -diethylamino) ethoxy] benzoyl] -6-methoxybenzofuran (N, N, N-isopropylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 2- (4-methoxyphenyl) -3- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] -6-methoxybenzofuran, 1-ethyl 2- (4-methoxyphenyl) -3- [4- [2 (piperidin-1-yl) ethoxy] benzoyl] -6-methoxyindole, 2- (4-methoxyphenyl) -3- [4- [3- hexamethyleneimin-1-yl) propoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2 (4-methoxyphenyl) -3- [4- [3- (piperidin-1-yl) propoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (pyrrolidine) 1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (N, N -diethylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (N, N-diisopropylamino) ethoxyl] benzoyl] benzo [b] thiophene, 2- (4-methoxyphenyl) -3- [4- [2- (N, N) -dimethylamino) ethoxy] benzoyl] benzo [b] thiophen e, 2- (4-Chlorophenyl) -3- [4- [2- (hexamethyleneimin-1-yl) ethoxy] benzoyl] -6-hydroxybenzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4] [2- (Piperidin-1-yl) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] benzo [ b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-diethylamino) ethoxyl] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-Diisopropylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-hydroxyphenyl) -3- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] benzo [b] thiophene, 2- (4-chlorophenyl) -3- [4- [2- (pyrrolidin-1-yl) ethoxy] benzoyl] benzo [b] thiophene-1-oxide, 2- (4-chlorophenyl) -3- [4- [2 (Piperidin-1-yl) ethoxy] benzoyl] benzo [b] thiophene-1-oxide, [6- (n-butylsulfonyl) -2- [4- (n-butylsulfonyl) phenyl] benzo [b] ] thien-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenylmethanone, [6- (n-pentylsulfonyl) -2- [4- (n-pentylsulfonyl) phenyl] benzo [b] thien-3 -yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (n-hexylsulfonyl) -2- [4- (n-hexylsulfonyl) ph enyl] benzo [b] thien-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (n-butylsulfonyl) -2- (4- (n-butylsulfonyl) phenyl] benzo [b] thien-3-yl] [4- [3- (1-piperidinyl) propyloxy] phenyl] methanone, [6- (n-butylsulfonyl) -2- [4- (n-butylsulfonyl] phenyl] benzo [ b] thien-3-yl] - [4- [2- (1-pyrrolidinyl) ethoxy] phenyl] methanone, [6-hydroxy-2- [4- (n-butylsulfonyl) phenyl] benzo [b] thien 3-yl] - [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6-n-butylsulfonyl-2- [4-hydroxyphenyl] benzo [b] thien-3-yl] - [4- [2- (1-Piperidinyl) ethoxy] phenyl] methanone, [6- [N- (4-chlorophenyl) carbamoyl] -2- [4- [N- (4-chlorophenyl) carbamoyl] phenyl] benzo [b] thien 3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N- (n-butyl) carbamoyl] -2- [4- [N- (n-butyl) carbamoyl] ] phenyl] benzo [b] thien-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-methylcarbamoyl) -2- [4- (N-methylcarbamoyl) phenyl] ] benzo [b] thien-3-yl] [- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-ethylcarbamoyl) -2- [4- (N-ethylcarb)] amoyl) phenyl] benzo [b] thien-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-isopropylcarbamoyl) -2- [4- [N-isopropylcarbamoyl)) phenyl] benzo [b] thien-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone, [6- (N-cyclohexylcarbamoyl) -2- [4- (N-cyclohexylcarbamoyl) phenyl] benzo [b] thienyl-3-yl] [4- [2- (1-piperidinyl) ethoxy] phenyl] methanone and their salts and solvates.

(b) Compounds of Formula (III): CH2CH2R2 ORa

in which Ro and R30, independently, represent H, CH3, -CO- (C1-C6) alkyl, optionally substituted phenyl and R20 represents pyrrolidino, piperidino, hexamethylenimino or their pharmaceutically acceptable salts or solvates, NPY-antagonists described in US 5,504,094, especially the compound of formula (III), in which Ro and R30 are both hydrogen and R20 is pyrrolidino, as well as their salts and solvates.

III - Phenylsulfonylquinolines of Formula (IV)

Wherein Ry is optionally substituted aryl, R'y is -NO2, -CN, -CO2R3y wherein R3y is H, alkyl or aryl, -SO2R3y wherein R3y is such that defined above, or S R3y O wherein R3y is as defined above, or R3y O wherein R3y is as defined above, O t1`1

- R2y is -NH2, -OH or -SH and its salts, described in US 5,552,411, including 8-amino-6- (2-isopropylphenylsulfonyl) 5-nitroquinoline known under the code PD-160170 and 8-amino-6 - (4-aminophenylsulfonyl) -5-nitroquinoline, known under the code PD-9262 described in Bioorganic and Medicinal Chemistry Letters, 1996, 6, 15, 1809-1814.

IV - Bénextramine and its analogs described in J. Med. Chem. 1993, 36, 272-279, in Eur. J. Pharmacology 1994, 37, 2242-2248 and in Current Pharmaceutical Design, 1995, 1, 295-304, especially the compounds SC3117, SC3199, CC217 and CC2137.

V - The derivatives of inositol phosphate, in particular chosen from: a) The specific isomers of inositol triphosphate, in particular D-myo-inositol-1,2,6-triphosphate, 1,2,3-myo-inositol -triphosphate and L-myo-inositol-1,3,4-triphosphate, described as NPY antagonists in WO 92/00079 and US 5,128,332. b) Inositol monophosphate in acid form and its salts, in particular of sodium, potassium, calcium or zinc, described as NPY antagonists in WO 92/00744 VI - Compounds of formula (V): in which: Ar 'is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each optionally mono or disubstituted by halogen, hydroxy, or lower linear alkyl chain or branched having 1 to 6 carbon atoms; - A ', W', X ', Y', and r are identical or different and represent a hydrogen, a halogen, a hydroxy, a linear or branched lower alkoxy chain having 1 to 6 carbon atoms; - R'1 and R'2 are identical or different and represent a hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; R'3 and R'4 are identical or different and represent a hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; and R'9 represents hydrogen, a straight or branched lower alkyl chain having 1 to 6 carbon atoms, or phenyl; and their salts, prepared as described in WO 96/14307, The preferred compounds according to formula (V) will be the following compounds: 1-cyano-1- (4-phenylpiperazin-1-yl) cyclohexane, 1-phenyl-1 - (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2-pyrimidinyl)) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2-pyridinyl) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) -1- [4- (2- (3-methoxyphenyl) -1- [4- (2-pyridinyl) piperazin-1-yl] cyclohexane; fluorophenyl) piperazin-1-yl] cyclohexane, 1- (3-methoxyphenyl) -1- [4- (4-fluorophenyl) piperazin-1-yl] cyclohexane, 1- (3-hydroxyphenyl) -1- (4-phenylpiperazine) -1-yl) cyclohexane, 1- (3,5-dimethoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane 1- (3-Methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-phenylcyclohexane, 1- (3-n-butoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcyclohexanedichloro cis -hydro isomer and trans isomer, 1- (4-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (2-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1 - (3,4-Methylenedioxyphenyl) -1- (4-phenylpiperazin-1-yl) cyclohexane, 1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcydohexane cis isomer and trans-isomer 1- (3-Ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-ethylcyclohexane isomer cis and isomer trans, 1- (3-isopropoxyphenyl) -1- (4-phenylpiperazin-1-yl) - 4-methylcydohexane cis isomer and trans isomer, 1- (3-methoxyphenyl) -1- (4-phenylpiperazin-1-yl) -3-methylcyclohexane isomer cis and isomer trans, 1- (3-benzyloxyphenyl) -1- (4 phenylpiperazin-1-yl) cyclohexane, 4- (3-ethoxyphenyl) -4- (4-phenylpiperazin-1-yl) tetrahydropyran, 4- (3-ethoxyphenyl) -4- (4-phenylpiperazin-1-yl) tetrahydrothiopyran 1- (3-Methoxymethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methylcyclohexane isomer cis and isomer trans, 1- (3-ethoxymethoxyphenyl) -1- Cis (4-phenylpiperazin-1-yl) -4-methylcyclohexane cis isomer and trans isomer, cis (1- (3-ethoxyphenyl) -1- (4-phenylpiperazin-1-yl) -4-methoxycydohexane cis isomer and trans isomer, VII- Compounds of formula (VI): TaZaNR1a (R2aCR3a) -CO-Ya (CH2) na Ra wherein - na represents 0, 1, 2, 3, 4, or 5; Ra represents a hydrogen atom, a phenyl or naphthyl group optionally mono- or disubstituted with an identical or different substituent chosen from a fluorine, chlorine, bromine or an iodine atom, a cyano or alkyl group, phenyl, hydroxy, alkoxy, dialkylaminoalkoxy, hydroxyphenyl, phenylalkoxy, alkylcarbonyl, amino, alkylamino, dialkylamino, alkylsulfonylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonyloxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyloxy, alkylsulfonyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, trifluoromethyl, trifluoromethoxy, trifluoro methylthio, aminoalkyl, alkylaminoalkyl, aminocarbonylaminoalkyl, benzoylamino, alkanoylaminoalkyl, alkoxycarbonylaminoalkyl, benzyloxycarbonylaminoalkyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonylamino, alkylaminosulfonylamino, dialkylaminosulphonylamin, cyanamino, am inocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, aminosulfonylaminoalkyle, alkylaminosulfonylaminoalkyle, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, aminosulfonylalkyl, alkylaminosulfonylalkyl, alkylsulfonyl, aminosulfonyloxy, alkylaminosulfonyloxy, dialkylaminosulfonyloxy or a group cyanoguanidino, an aminophenyl group or aminonaphtyle disubstituted by chlorine or bromine atom, the substituents which may be the same or different, or a hydroxyphenyl or hydroxynaphthyl group disubstituted by a chlorine or bromine atom or by alkyl or alkoxy groups, the sub-components may be identical or different, a diphenylmethyl group, a substituted aminocarbonylalkyl group on the alkyl part with a hydroxyphenylalkyl group or a (2,2-diphenylethyl) aminocarbonylaminophenyl group, a 5-membered heteroaryl group connected by a carbon or nitrogen atom, said heteroaryl ryl comprising an imino group optionally substituted by a (C1-C6) alkyl group or a phenyl group and an oxygen, sulfur or nitrogen atom, or a 6-membered heteroaryl group connected by a carbon atom, said heteroaryl comprising one or two nitrogen atoms, as well as the 5- or 6-membered heteroaromatic rings defined above which constitute a heteroaromatic bicycle with two carbon atoms neighboring the heteroaromatic ring and a 1,4-butadienylene group and further, all the mono- or bicyclic heteroaryl groups mentioned above may be monosubstituted on the carbon skeleton by a fluorine, chlorine or bromine atom, by an alkyl, alkoxy, hydroxy, phenyl, nitro, cyano, carbonyl or alkoxycarbonyl group, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoro methyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl, or disubstituted by n fluorine, bromine or chlorine atom, with methyl, methoxy or hydroxy groups, the substituents possibly being identical or different, a phenyl group substituted by a (1,5-dihydro-2,4 (3H) -dioxo imidazol-3-yl) alkyl or with a [1,2-dihydro-3,5 (4H) -dioxo-3H-1,2,4-triazol-4-yl] alkyl residue, wherein the imidazole or triazole moiety is substituted with 1 or 2 phenyl groups, a cycloalkyl group having from 4 to 8 carbon atoms optionally substituted by a hydroxy, amino, alkylamino or dialkylamino group, the substituents described above not being linked to the position 1 of the remainder cycloalkyl, when Y represents an oxygen atom, a group 1 - [[[5,11-dihydro-6 (6H) -oxo-pyrido [2,3-b] [1,4] benzodiazepin-11-yl] carbonyl] methyl] -4-pipéhdinyl or a 3-hydroxy-1-propin-1-yl group, a 2,3-dihydro-1H-isoindol-2-yl group optionally substituted on the nitrogen atom by a group diphenylaminocarbonyl, or a hydroxy group, when Y is an oxygen atom e or a group -NR4a- and na represents a number between 2 and 5, - Ria is a hydrogen aroma, a linear or branched (C1-C10) alkyl group, a cycloalkyl group having from 3 to 7 carbon atoms, a phenyl group optionally substituted with a hydroxy or hydroxyalkyl group, or a phenylmethyl group optionally substituted on the phenyl part by a hydroxy or hydroxyalkyl group; - R2a is a non-branched (C1-05) alkyl substituted in the omega position with an amino group or alkylamino protected by a protecting group of the amine group, with a dialkylmino, N-alkylbenzylamino, aminocarbonyl, aminocarbonylamino, aminoethylimine, aminoiminomethyl, amino (hydroxyimino) methyl, amino (alkoxyimino) methyl, amino (nitroimino) methyl, [amino (nitroimino) methyl] amino, amino (cyanimino) methyl, [amino (cyanimino) methyl] amino, [(alkylamino) iminomethyl] amino, [(alkylamino) (alkylimino) methyl] amino, [amino (alkylimino) methyl] amino, 2-amino imidazol-1-yl (5-amino) 4H-1,2,4-triazol-3-yl) amino, (5-amino-4H-1,2,4-triazol-3-yl) methylamino, (3-amino-1,2,4-oxadiazole) 5-yl) amino or (5-amino-1,2,4-oxadiazol-3-yl) amino or imidazol-4-yl, imidazol-2-yl, 1-methyl-imidazol-2-yl, imidazol-2-yl-amino, imidazol-2-yl-methylamino, (4,5-dihydro-1H-imidazol-2-yl) amino optionally substituted on the carbon by one or two methyl groups, or a phenyl group or phenylmethyl optionally substituted on the aromatic rings by cyano, iminomethylamino, cyaniminomethylamino, (methylamino) methyl idenamino, aminoiminomethyl, amino- (hydroxyimino) methyl, amino (alkoxyimino) methyl, hydrazinoiminomethyl, amino (cyanimino) methyl or guanidino or by a group imidazol-2-yl, 1-methyl-imidazol-2-yl, 4,5-dihydro-1H-imidazol-2-yl optionally substituted on the carbon atoms by one or two methyl groups, wherein in the aminoiminomethyl groups , amino (hydroxyimino) methyl and guanidino mentioned s in the definition of R2a above, one or more hydrogen atoms connected to the nitrogen atom, independent of each other, may be replaced by alkyl groups or in which two hydrogen atoms connected to different Nitrogen atoms may be replaced by an alkyl bridge having 2 to 4 carbon atoms and for which the hydrogen atom of a group HN <, HN = or H 2 N in the radical R2a may be substituted by an alkoxycarbonyl group having of 2 to 7 carbon atoms, with a phenylalkoxycarbonyl group in which the alkyl is (C1-C6), phenyloxycarbonyl, R15a-CO-O- (R16aCR17a) -O-CO or a group ( R18aO) PO (OR19a) wherein: R15a is a (C1-C15) alkyl group, a (C3-C7) cycloalkyl group, a phenyl group or a phenylalkyl group in which the alkyl is (C1-C3), R16a and R17a, which may be identical or different, represent a hydrogen atom, a (C1-C6) alkyl group, or one of the radicals R16a and R17a representing (C3-C7) cycloalkyl group or a phenyl group, R18a and R19a, which may be identical or different, represent a hydrogen atom, (C1-C4) alkyl groups, benzyl or phenyl groups, Ria is a hydrogen, a (C1-C7) alkyl group or a (C4-C7) cycloalkyl group, Ta is a hydrogen atom, a phenyl group or a 5-membered heteroaryl group connected by a carbon or nitrogen atom and comprising a nitrogen, oxygen or sulfur atom optionally substituted by an alkyl group, or comprising a nitrogen atom optionally substituted by an alkyl group and an additional sulfur, oxygen or nitrogen atom; or when Za is a bond, Ta is a protecting group of an amino group or the moieties (T1aT2aUa) - (CH2) n - or T3,0-, wherein T1a to T3a, the same or different are phenyl groups or 6-membered heteroaryl groups linked by carbon atoms, which depending on the case one or two nitrogen atoms, 5-membered heteroaryl groups connected by carbon or nitrogen atoms, comprising a nitrogen atom optionally substituted with an alkyl, sulfur or oxygen group, or comprising an atom nitrogen optionally substituted by an alkyl group and a nitrogen, sulfur or additional oxygen atom, in which a 1,4-butadienylene bridge may be formed between two carbon atoms neighboring the 5-membered heteroaryl groups; 6 links mentioned above in the definition of Ta remains; the bicyclic aromatic or heteroaromatic rings thus formed may also be bonded to a carbon atom of the 1,4-butadienylene group and, moreover, both the phenyl groups, the 5 or 6-membered heteroaryl groups and the bicyclic aromatic or heteroaromatic rings may be mono or disubstituted on the carbon skeleton by fluorine, chlorine, bromine or iodine atoms or by cyano, hydroxy, amino, dimethylamino, diethylamino, N-ethyl-methylamino, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, acetylamino groups, propionylamino, methanesulfonylamino, methansulfonyloxy, phenyl, phenylmethoxy, 2-phenylethoxy, alkyl, or alkoxy or trisubstituted with an amino or hydroxy group and two chlorine or bromine atoms or with a hydroxy group and two alkyl or alkoxy groups, the substituents being identical or different, and the alkyl and alkoxy moieties mentioned above comprising from 1 to 4 carbon atoms, hydrogen atoms, (C1-C12) alkyl groups, cycloalkyl groups having 3 to 10 carbon atoms, bicycloalkyl or tricycloalkyl groups having 6 to 12 carbon atoms or T'a and T2a together represent a linear chain (C 3 -C 7) alkylene group, Ua is the> CH group, in which the hydrogen atom may be replaced by an alkyl, phenyl, hydroxy, alkoxy, alkanoyloxy, alkoxycarbonyl alkanoylamino group, wherein the alkyls or alkoxys mentioned above may comprise, according to the case of 1 to 3 carbon atoms, and the alkanoyls mentioned above may comprise 2 or 3 carbon atoms, or the> CHCH 2 - group or the atom of nitrogen, m represents 0, 1, 2, or 3 or Ta is a group (T'aT2aUa) - (CH2) ,,, in which, T'a, T2a, Ua and ma are as defined above except that the mono- or bicyclic aromatic or heteroaromatic rings mentioned above for T'a and T2a are s between them by a bond, a -CH2-, -C (CH3) 2-, -CH2CH2-, -CH = CH- or -NHCO- bridge, Ya is an oxygen atom or a group -NR4a, in wherein R4a is as defined above with Ria, the residues of Ria and R4a being the same or different, and Za is a single bond defined by a -CO-, -CH2-, -SO-, or -SO2 group and, unless otherwise mentioned, the alkyl and alkoxy moieties mentioned above may comprise from 1 to 3 carbon atoms, and the tautomers, diastereomers, enantiomers, mixtures and salts of these compounds described in WO 94/17035. .

Among these compounds, the following compounds are particularly preferred: (R) -N2- (diphenylacetyl) -N- (phenylmethyl) argininamide, (R) -N2- (diphenylacetyl) -N - [(4-methylphenyl) methyl] argininamide, (R) -N- [2- (4-hydroxyphenyl) ethyl] -N2 - [[5- (2-phenylethoxy) -1H-indol-2-yl] carbonyl] argininamide, N - [(4-aminocarbonylaminophenyl) methyl] -N2- (diphenylacetyl) arginine, (R) -N - [(4-hydroxyphenyl) methyl] -N2 - [[5- (2-phenylethoxy) -1H-indol-2-yl] carbonyl] arginamide (R) -N2- (diphenylacetyl) -N - [(4-fluorophenyl) methyl] argininamide, (R) -N - [(4-bromophenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2 - (Diphenylacetyl) -N- (2-phenylethyl) argininamide, optically active diastereoisomers of N2- (alpha-cyclopentylphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -D-argininamide, N - [[4- (dimethylamino) ) phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [[4- (hydroxymethyl) phenyl] methyl] argininamide, (R) -N2- (diphenylacetyl) -N- [[4- (1-oxoéth yl) phenyl] methyl] argininamide, (R) -N - [(4-chlorophenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) -N - [[4 - [(methylaminocarbonyl)) amino] phenyl] methyl] argininamide, (R) -N - [(4-amino-3,5-dichlorphenyl) methyl] -N2- (diphenylacetyl) arginamine, (R) -N - [(4-amino) 3,5-dichlorphenyl) methyl] -N2 (3,3-diphenyl-1-oxopropyl) argininamide, (R) -N - [(4-amino-3,5-dichlorphenyl) methyl] -N2- (3,4-dichlorophenyl) methyl dichlorobenzoyl) argininamide, N2- (diphenylacetyl) -N- [3- [1- [2- [5,11-dihydro-6 (6H) -oxopyrido [2,3-b] [1,4] benzodiazepine 5-yl] -2-oxoethyl] -4-piperidinyl] propyl] arginine, N2- (diphenylacetyl) -N - [(4-hydroxy-3-methoxyphenyl) methyl] argininamide, N2- (diphenylacetyl) -N- [(3-Hydroxy-4-methoxyphenyl) methyl] arginamine, (R, S) -N - [(4-amino-3,5-dibromphenyl) methyl] -N6- (aminoiminomethyl) -N2- (diphenylacetyl) lysinamide, N - [(3,5-dimethyl-4-hydroxyphenyl) methyl] -N2- (diphenylacetyl) argininamide, N - [(1H-benzimidazol-5-yl) methyl] -N2- (diphenylacetyl) argininamide, N2 - ( diphenylacetyl) -N - [(4-hydroxy-3-methylphenyl) methyl] argininamide, N - [[4- (aminocarbonyl) phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R, S) -N6- (aminoiminomethyl) ) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] lysinamide, (R) -N - [(4-hydroxyphenyl) methyl] -N2- (phenylacetyl) argininamide, N2- (diphenylacetyl) -N- [(1 H -indol-5-yl) methyl] arginamide, (R) -N - [[4- (aminosulfonyl) phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) - N - [[4-methoxycarbonyl) phenyl) methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [(4-pyridinyl) methyl] arginaminamide, (R) -N - [(4-amino-3) 5-dibromphenyl) methyl] -N2- (diphenylacetyl) arginamine, (R) -N2- (diphenylacetyl) -N - [(2-thienyl) methyl] -N2- (2-naphthoyl) argininamide, (R) N - [(4-amino-3,5-dichlorphenyl) methyl] -N2- (2-naphthoyl) argininamide, (R, S) -N5- (4,5-dihydro-1H-imidazol-2-yl) ) -N 2 - (Diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] aminoethylamine, (R, S) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -N5- (1 H-imid azol-2-yl) ornithinamide, (R) -N - [[3 - [(1,2-dihydro-3,5 (4H) -dioxo-1,2-diphenyl-3H-1,2,4-triazole 4-yl) methyl] phenyl] -N2- (diphenylacetyl) argininamide, N2- (diphenylacetyl) -N - [(3-hydroxyphenyl) methyl] argininamide, (R) -N - [[3 - [(4,5 2,4-dihydro-2,4 (3H) -dioxo-5,5-diphenyl-1H-imidazol-3-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide, (R) -N2- (diphenylacetyl) N - [(4-hydroxyphenyl) methyl] argininamide, known by its code BIBP3226, N2- (diphenylacetyl) -N- [2- (4-hydroxyphenyl) ethyl] argininamide, N2- (diphenylacetyl) - [(4'- hydroxy- [1,1'-biphenyl) -4-yl) methyl] argininamide, N - [[4 - [(1,2-dihydro-3,5 (4H) -dioxo-1,2-diphenyl-3H- 1,2,4-triazol-4-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide, N2- (diphenylacetyl) -N - [(4-methoxyphenyl) methyl] argininamide, N2- (diphenylacetyl) - N- [2- (4-methoxyphenyl) ethyl] argininamide, N 2 - (diphenylacetyl) -N- [2- (3-methoxyphenyl) ethyl] arginamine, N 2 - (diphenylacetyl) -N - [(3-methoxylphenyl) ) methyl] argininamide (R, S) -3- [4- (aminoiminomethyl) phenyl] -N2- (d-phenylacetyl) -N - [(4-hydroxyphenyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (d-phenylacetyl) ) -N - [(4-methoxyphenyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] alaninamide, (R) -N2- [bis- (4-bromophenyl) acetyl] -N - [(4-hydroxyphenyl) methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [(4-ethoxyphenyl) methyl] argininamide (R) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] -N-methylargininamide, (R, S) -N - [(4-amino-3,5-dibromphenyl) methyl] -3 - [3- (aminoiminomethyl) phenyl] -N2- (diphenylacetyl) alaninaminde, (R) -N - [(4-hydroxyphenyl) methyl] -N2- (2-naphthoyl) argininamide, (R) -N - [(4) hydroxyphenyl) methyl] -N2- (2-naphthoyl) argininamide, (R) -N2- (2,2-diphenyl-2-hydroxyacetyl) -N - [(4-hydroxyphenyl) methyl] argininamide, (R, S) N, 2- (Diphenylacetyl) -N5- (1H-imidazol-2-yl) -N - [(4-methoxyphenyl) methyl] ornithinamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2 - [ [(Diphenylmethyl) amino] carbonyl] -N - [(4-hydroxyphenyl) methyl] alaninamide, (R, S) -N2- (diphenylacetyl) -N5- (1H-imidazol-2-yl) -N- (phenylmethyl) ) -omithinamine, (R, S) -N - [(4-amino-3,5-dichlorphenyl) methyl] -N2- (diphenylacetyl) -N5- (1H-imidazol-2-yl) -ornithinamide, (R) S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2- (2-naphthoyl) -ornithinamide, (R, S) -N2 - [[(diphenylmethyl) ) amino] carbonyl] -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2 - [(2-naphthyl) acetyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-) yl) -N2 - [[(2-naphthyl) amino] carbonyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] -N5- (1H-imidazol-2-yl) -N2- [(1,2,3,4-tetrahydroquinolin-3-yl) carbonyl] ornithinamide, (R, S) -N - [(4-hydroxyphenyl) methyl] N5- (1H-imidazol-2-yl) N2 - [(1,2,3,4-tetrahydroquinolin-2-yl) carbonyl] ornithinamide, (R) -N - [(4-aminosulfonylaminophenyl) methyl] -N2- (diphenylacetyl) arginine (R) -N - [(4-aminophenyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N - [(6-quinolinyl) methyl] -N2- (diphenylacetyl) argininamide, (R) -N2 - [(3,4-dichlorophenyl) acetyl] -N - [(4-hydroxyphenyl) methyl] argininamide, (R) -N2- (diphenylacetyl) -N - [[4- (2-hydroxyethyl) phenyl] methyl] argininamide (R, S) -N5- (3-Amino-1,2,4-oxadiazol-5-yl) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] ornithidine, (R ) -N2 - [(9-fluorenyl) carbonyl] -N - [(4-hydroxyphenyl) methyl] argininamide, (R, S) -6- (aminoiminomethyl) -N2- (d-phenylacetyl) -N - [(4- hydroxyphenyl) methyl] norleucinamide, (R, S) -3- [4- (4,5-dihydro-1H-imidazol-2-yl) phenyl] -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] alaninamide, (R, S) -3- [3- (aminoiminomethyl) phenyl] -N2- (d-phenylacetyl) -N - [(4-ethoxycarbonyloxyphenyl) methyl] alaninamide, (R, S) -N- [ 2- (1,2-Dihydro-1,2-diphenyl-3,5 (4H) -dioxo-1,2,4-triazol-4-yl) ethyl] -N2- (diphenylacetyl) argininamide, (R, S) ) -N 2 - (d-phenylacetyl) -N - [(4-hydroxyphenyl) melhyl] -2-methylargini Namide, (R, S) -N2- (diphenylacetyl) -N - [[4- (3-hydroxypropyl) phenyl] methyl] argininamide, (R) -N - [[4 - [(4,5-dihydro-5 5-dimethyl-2,4 (3H) -dioxo-1H-imidazol-3-yl) methyl] phenyl] methyl] -N2- (diphenylacetyl) argininamide. VIII - The compounds of formula: ## STR2 ## in which R "is defined by the formula:

Wherein R "1 represents a phenyl group unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl group or a pyridinyl ring unsubstituted or substituted by one or two halogen atoms, a group (C1-C3) alkyl or a (C1-C3) alkoxy group, - R "2 represents a hydrogen atom, a (C1-C3) alkyl group, a phenyl group optionally substituted with one or two halogen atoms or by a (C1-C3) alkyl group or by a (C1-C3) alkoxy group, a benzyl or heteroaryl group unsubstituted or substituted by one or two halogen atoms or a (C1-C3) alkyl group or (C1-C3) -C3) alkoxy, n "represents 1, 2, 3 or 4 or wherein R" is defined by the formula: R "3

Wherein R "3 represents a pyridinyl ring which is unsubstituted or substituted by one or two halogen atoms, by a group (Cl-4); C3) alkyl or (C1-C3) alkoxy, R "4 represents a hydrogen atom or a phenyl group optionally substituted by one or two halogen atoms or by a (C1-C3) alkyl group or by a group (Cl -C3) alkoxy, R "5 represents a hydrogen atom or a methyl group (VII) R 2 / N- (CH 2) n., 5 or hydroxy and Z" represents a single bond, an oxygen atom, or a sulfur atom and p "represents 1, 2 or 3, m" represents 1,2 or 3 and R "O represents a hydrogen atom or a methyl group, as well as their pharmaceutically acceptable salts, whose antagonistic effect is NPY is described in EP 0 448 765. IX - Dihydropyridines of formula: x R5 x (CH2) - Z (VIII) in which - R1x is lower alkyl; R2x and R3x are independently selected from cyano and lower alkyl; - R4x is selected from -CO2R1X, cyano and pùN CH3 - R5X is selected from hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyloxy and lower alkoxy; Bx is -NH- or a covalent bond; nx represents an integer of 2 to 5 and - ZX is selected from the group consisting of: N 20 And the solid or dotted lines representing a single or double bond, as well as their addition salts or solvates described in US 5,554,621 .

X - The compounds of formula:

Tyr-Pro-Ser-Lys-Pro-Asp-D-Cys-NH- (CH2) s-CO-Xxx2-Arg-Cys-Tyr-Xxx3-Ala-Leu-Arg-His-Tyr-Xxx4-Asn- Leu-Xxx5-Thr-Arg-Ile-Arg-Tyr-Tc (IX) in which - Xxx2 and Xxx3 are Ser or Ala, - Xxx4 and Xxx5 are Leu, IIe, Met, NIe (Norleucine) or Val - Tc is OH , O (C1-C4) alkyl, NH2 or NH (C1-C4) alkyl, s is an integer from 1 to 11, and their salts, described in EP 0 355 794.

XI - The compounds of formula:

Wherein k1, k2, k3, k4, k5, k6 and k7 are zero or 1; , their sum being at least 1, A is Phe or Tyr, B is Pro, Ser, Ala, Gly, Abu, Cys, Pro-Ser, Cys-Ser, Ala-Ser, Gly-Ser, Abu-Ser or Pro- Ala, Abu being 2-aminobutyric acid, BP, BP 'and BP "are amino acids with a basic side chain; D is Pro or Cys; E is NH- (CH2) t-CO, t being 0-10; F is Cys, Abu Gly or Ala; G is IIe-Asn, Leu-Asn, Val-Asn or Asn; DP is the residue of a dipeptide formed by lipophilic amino acids; K is Phe or Tyr; Zb is hydrogen, an amino-protecting group or a benzyl, (C2-C10) acyl or (C1-C5) alkyl group and in which two Cys residues may be linked by a disulfide bridge, as well as their salts, described in DE 3 939 801.

Among these compounds, those of formula (X) in which BP is Lys or Arg; E is NH- (CH2) t-CO, with t = 1-7; F is Cys or Abu; G is IIe-Asn or Asn; DP is Leu-Ile, BP 'and BP ", the same, are Arg, Zb is hydrogen, acetyl or a group where t' is 0, 1 or 2, and their salts are advantageous, the compound of formula:

H-Tyr-Abu-Ser-Lys-Aoc-Abu-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 where Aoc represents 8-aminooctanoic acid being particularly preferred. XII - Cyclic or linear compounds, of formula:

(XI) (XXXa-XXXb-XXXc-xxxxxxxxxxxxxxxxxxxxx) where Xxxa, Xxxb, Xxxc, and Xxxi may not exist, or Xxxa is P1 or Cys; Xxxb is Cys, P1 or one or two amino acids; Xxxc is P1, Cys, Ser, Thr, Ala, or Gly; Xxxd is R1, Cys, Ser, Thr, Ala or Gly; Xxxe is Leu, Ile, Val or Nle; Xxxg is Arg, Lys or His; Hxxg is Arg, Lys, His, Val, Leu, Ile or Nle; Xxxh is Tyr, Phe, Trp, His, Lys or Arg; Xxxi represents an NH2 group or an ester group or one or two amino acids; Xxxi is Cys or P2; P1 is hydrogen or a P-CO group where P is hydrogen, a glycosyl, nucleosyl or lipolyl radical or a (C1-C20) alkyl group, optionally containing double bonds and substituents chosen from halogens and the group NO 2, NH 2, OH, sulfo, phospho, carboxy and alkyl; P2 is NP12P13 or OP14 wherein P12 and P13 are hydrogen or alkyl, cycloalkyl, N-glycosyl, N-lipolyl, aralkyl or aryl, optionally substituted with halogen or with NO2, NH2, OH, sulfo, phospho, carboxy or alkyl; and P14 represents hydrogen or an alkyl, cycloalkyl, aralkyl, -O-glycosyl, -O-Iipolyl, aralkyl or aryl group, optionally substituted by a halogen or a NO2, NH2, OH, sulfo, phospho, carboxy or alkyl, with the limitation that - when Xxxb does not exist or represents Cys or P1, then Xxxa is non-existent, - when Xxxd is Cys or P1, then Xxxc is non-existent, - when Xxxi is NH2 or an ester, then Xxxi is non-existent .

These compounds are described in WO 93/12139. The compound Ser-Ala-Leu-Arg-His-Tyr-NH 2 is described in particular.

XIII - Compounds of formula:

H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu- (XII) Asp-Ala-Pro-Ala-Glu-Asp-Xxxb-Ala-Arg-Tyr-Tyr-Ser-Ala -Leu-Arg-H is-Tyr-I-Asn-Leu-IIe-Thr-Arg-Xxx, -Xxxe-L1- (CH2) z-P3 wherein z is 0.1 or 2. Xxx6 is Met or Leu; Xxx7 is Glu, (R) -Glu, Pro or (R) -Pro; Xxx8 is Arg, (R) -Arg or (R, S) -Arg; L1 is O or NP ', P' being H or alkyl; and P3 is phenyl or naphthyl unsubstituted or substituted with one or two F, Cl, Br, alkyl, phenyl, OH, (phenyl) alkoxy, alkylcarbonyl, NH2 (optionally substituted by one or two alkyls), alkylsufonyl, alkyl or alkoxycarbonylamino, COOH, alkoxycarbonyl, NH 2 CO (optionally substituted with one or two alkyls), alkylcarbonyloxy, alkylsulphonyloxy, CH 2 OH, 1- or 2-hydroxyethyl, (alkyl) aminosulfonyl, cyanamino, aminocarbonylamino (optionally substituted with one or two alkyls) or NH2C (= N.CN) NH; a 5-membered aromatic heterocycle containing oxygen, sulfur or nitrogen, an imino group or an imino group containing oxygen, sulfur or nitrogen; a 6-membered aromatic heterocycle with one or two nitrogen atoms; said heterocycles may be C-substituted by (C 1 -C 6) alkyl or phenylalkyl and optionally fused to benzene and optionally also substituted by F, Cl, Br, (C 1 -C 6) alkyl, alkoxy, OH, phenyl, NO 2, NH 2 (optionally substituted by one or two alkyls or an alkanoyl), CN, COOH, alkoxycarbonyl, NH 2 CO (optionally substituted by one or two alkyls), CH 2 F, CHF 2, CF 3, alkanoyl or NH 2 SO 2 (optionally substituted with one or two alkyls) or with two F, Cl, Br, methyl, methoxy or OH; a phenyl group substituted by a [1,5-dihydro-2,4- (3H) -dioxoimidazol-3-yl] alkyl group or by a [3,5-dihydro-4H-dioxo-3H-1 group] 2,4-triazol-4-yl] alkyl of which the imidazole and triazole groups may be substituted by one or two phenyls; alkyl and alkoxy groups containing from 1 to 3 carbon atoms, and their salts. These compounds are illustrated in DE 4 311 756. XIV. Preparative NPY antagonists according to WO 94/00486, JP 06-116284, JP 07-267988, DE 3,811,193, US 5,328,899 and WO 95/00161, such as the compound (X111) CH3CO-D-Cys-Leu-Iie-Thr-Arg-C! s-Arg-Tyr-NH 2 described in JP 06-116284 and the compound (XIV): Cys-Pro-Cys-Tyr-Arg-Leu-Arg-Tyr-NH2 1 Ie-Cys-Pro-Cys-Tyr -Arg-Leu-Arg Tyr-NH2 described in WO 94/00486.

XV - The extracts with antagonistic activity of NPY obtained by extraction of a spongiary, Orina sp. Gray (or Gellius sp.) And in particular the compounds derived from indole described in J. Nat. Products, 1994, 57, 1294-1299 and ibid 1995, 58, 8, 1254-1260, or mixtures thereof and more particularly gelliusin A, gelliusin B, 2- [5-hydroxy-3- (2-aminoethyl) )] indol-2-yl-6-bromo-3-indoleethanamine, 2- [6-bromo-3- (2-aminoethyl)] indol-2-yl-6-bromo-3-indoleethanamine, their salts and their mixtures. (XIII) (XIV) XVI - Fermentations extracts of strains of Aspergillus, for example Aspergillus piger with NPY antagonistic activity and in particular the compound known by the code name BMS-192548, preparable by extraction of the culture medium of Aspergillus niger WB 2346, as described in J. Antibiotics, 1995, 48, 10, 1055-1059 and having the formula (XV): CH3O (XV) H3 OH XVII - The products and in particular the extracts obtained by fermentation of strains of Actinomycetaceae, having an NPY antagonist activity, these strains and their culture being described in document EP 0 838 217 (the preferred strain is the strain I-1332 deposited with the National Collection of Microorganism Cultures (CNCM)). 'Pastor Institute).

XVIII - Vegetable products, especially extracts obtained from Cynara scolymus.

Those skilled in the art will be able to adjust the concentration of NPY antagonist agent depending on the desired effect, namely a volumizing or repulping effect and / or the natural coloring of the lips, and the activity of said antagonist. This concentration may be between 10-8 and 10% by weight relative to the total weight of the composition, preferably from 10-6 to 5% and better still from 10-4 to 2%, and more preferably 10-2. at 1% by weight relative to the total weight of the composition.

Advantageously, said agent used according to the invention may be incorporated into a system allowing its release at the lips, after application of the composition thereon.

In particular, said agent may be adsorbed or incorporated into particle structures of size ranging from 1 nm to a few pm (10 μm), such as, for example, microcapsules, microparticles, ionic-type vesicular dispersions (liposomes or oleosomes) and or nonionic (niosomes) and / or nanosphere dispersions. These particles may be advantageously porous and consist of silicates or aluminosilicates. Examples of such formulations are described in particular in patents EP 0 199 636, EP 0 375 520, EP 0 447 318, EP 0 557 489, WO 97/12602, EP 1 151 741 or US 5,914,126.

By way of example, the microspheres may be prepared according to the method described in patent application EP 0 375 520. The nanospheres may be in the form of an aqueous suspension and may be prepared according to the methods described in patent applications FR 00 15686. and Oleosomes consist of an oil-in-water emulsion formed by oily globules provided with a lamellar liquid crystal coating dispersed in an aqueous phase (see patent applications EP 0 641 557 and EP 0 705 593). The agent according to the invention may also be encapsulated in nanocapsules consisting of a lamellar coating obtained from a silicone surfactant as described in patent application EP 0 780 115; the nanocapsules may also be prepared based on water-dispersible sulfonic polyesters according to, for example, the technique described in the patent application FR 01 13337.

The compositions according to the invention may also comprise at least one agent chosen from solvents, oils, waxes, pastes, gums, fillers, dyestuffs, cosmetic active agents, thickeners, surfactants, moisturizers, softeners, sequestering agents, perfumes, neutralizers, preservatives, antioxidants, bactericides, trace elements, odor absorbers and mixtures thereof. The amounts of these different agents are those conventionally used in the field under consideration, for example from 0.01 to 20% of the total weight of the composition.

The composition may be in any galenical form normally used for topical application and especially in anhydrous form, in the form of an oily or aqueous solution, an oily or aqueous gel, a water-in-water emulsion or water-in-water. in-oil, a multiple emulsion, an oil dispersion in water through vesicles located at the oil / water interface. The composition of the invention may be in the form of a liquid, a solid or a semi-solid, especially a product cast in a stick or a dish, a stick, a paste, or a more or less fluid cream. The composition of the invention can be obtained according to the preparation methods conventionally used in cosmetics.

By physiologically acceptable medium is meant a medium compatible with the lips of humans.

The physiologically acceptable medium will be adapted to the nature of the support on which the composition is to be applied and to the form in which the composition is intended to be packaged, especially solid or fluid at ambient temperature and atmospheric pressure.

The composition according to the invention may comprise an aqueous cosmetic medium and / or a fatty phase. The composition may comprise water or a mixture of water and hydrophilic organic solvents such as alcohols and in particular linear or branched lower monoalcohols having from 2 to 5 carbon atoms, such as ethanol, isopropanol or n-butanol. propanol, polyols such as glycerine, diglycerine, propylene glycol, sorbitol, penthylene glycol, polyethylene glycols. The hydrophilic phase may, in addition, contain C2 ethers and hydrophilic C2-C4 aldehydes. The water or the mixture of water and hydrophilic organic solvents may be present in the composition according to the invention, or one of the base and / or surface compositions, in a content ranging from 0% to 90% ( in particular 0.1% to 90% by weight, relative to the total weight of the composition, and preferably from 0% to 60% by weight (in particular 0.1% to 60% by weight).

The composition may also comprise a fatty phase, especially consisting of fatty substances that are liquid at room temperature (generally 25 ° C.) and / or fatty substances that are solid at room temperature, such as waxes, pasty fatty substances, gums and their mixtures. . This fatty phase may, in addition, contain lipophilic organic solvents.

As liquid fatty substances at room temperature, often called oils, which can be used in the invention, mention may be made of: vegetable hydrocarbon-based oils such as liquid triglycerides of fatty acids with 4 to 10 carbon atoms, such as triglycerides of heptanoic or octanoic acids or sunflower, corn, soybean, grape seed, sesame, apricot, macadamia, castor oil, avocado oil, caprylic / capric acid triglycerides, jojoba oil, shea butter; linear or branched hydrocarbons of mineral or synthetic origin, such as liquid paraffins and derivatives thereof, petroleum jelly, polydecenes, hydrogenated polyisobutene such as parleam; esters and synthetic ethers, in particular of fatty acids, for example purcellin oil, isopropyl myristate, 2-ethylhexyl palmitate, octyl-2-dodecyl stearate, erucate octyl-2-dodecyl, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters such as propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate; and pentaerythritol esters; fatty alcohols having 12 to 26 carbon atoms such as octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol; partially hydrocarbon and / or silicone fluorinated oils; silicone oils, such as volatile or nonvolatile polymethylsiloxanes (PDMS), linear or cyclic, liquid or pasty at room temperature, such as cyclomethicones, dimethicones, optionally comprising a phenyl group, such as phenyl trimethicones, phenyltrimethylsiloxydiphenylsiloxanes or diphenylmethyldimethyltrisiloxanes, diphenyl dimethicones, phenyl dimethicones, polymethylphenyl siloxanes; their mixtures. These oils may be present in a content ranging from 0.01 to 90%, and better still from 0.1 to 85% by weight, relative to the total weight of the composition. The composition of the invention may further advantageously comprise a solid or pasty fatty substance at room temperature, such as gums or waxes.

The waxes may be hydrocarbon-based, fluorinated and / or silicone-based and may be of vegetable, mineral, animal and / or synthetic origin. In particular, the waxes may have a melting point greater than 25 ° C. and better still greater than 45 ° C. As waxes that may be used in the composition of the invention, mention may be made of beeswax, carnauba wax, candelilla wax, paraffin wax, microcrystalline waxes, ceresin or ozokerite; synthetic waxes such as polyethylene or Fischer Tropsch waxes, silicone waxes such as alkyl or alkoxy dimethicone having from 16 to 45 carbon atoms.

The gums which can be used are generally high molecular weight polydimethylsiloxanes (PDMS) or cellulose gums or polysaccharides and the pasty substances are generally hydrocarbon compounds such as lanolines and their derivatives or else PDMSs.

Paste means a lipophilic fat compound with reversible solid / liquid state change, comprising at the temperature of 23 ° C. a liquid fraction and a solid fraction. Paste is also understood to mean vinyl polylaurate.

The pasty compounds are advantageously chosen from: lanolin and its derivatives, fluorinated compounds which are polymeric or non-polymeric, polymeric or non-polymeric silicone compounds, vinyl polymers, in particular: homopolymers of olefins, copolymers of olefins - homopolymers and copolymers of hydrogenated dienes - linear or branched oligomers, homo or copolymers of alkyl (meth) acrylates preferably having a C 8 -C 30 alkyl group - homo and copolymeric oligomers of vinyl esters having C8-C30 alkyl groups - homo- and copolymer oligomers of vinyl ethers having C8-C30 alkyl groups, - liposoluble polyethers resulting from the polyetherification between one or more C 2 -C 10 0 diols, preferably C 2 -C 50 diols, esters, and mixtures thereof.

Among the liposoluble polyethers, copolymers of ethylene oxide and / or of propylene oxide with long-chain C 6 -C 30 alkylene oxides are preferred, more preferably such as the weight ratio of ethylene oxide. and / or propylene oxide with alkylene oxides in the copolymer is from 5:95 to 70:30. In this family, mention will in particular be made of copolymers such as long-chain alkylene oxides are arranged in blocks having an average molecular weight of 1,000 to 10,000, for example a polyoxyethylene / polydodecyl glycol block copolymer such as dodecanediol ethers (22). mol) and polyethylene glycol (45 0E) marketed under the tradename ELFACOS ST9 by Akzo Nobel.

Among the pasty esters, the following are particularly preferred: esters of an oligomeric glycerol, in particular the diglycerol esters, in particular the condensates of adipic acid and of glycerol, for which part of the hydroxyl groups of the glycerols have reacted with a mixture fatty acids such as stearic acid, capric acid, stearic acid and isostearic acid and 12-hydroxystearic acid, especially in the image marketed under the trademark Softisan 649 by the company Sasol arachidyl propionate sold under the name Waxenol 801 by Alzo; phytosterol esters; non-crosslinked polyesters resulting from the polycondensation between a linear or branched C 4 -C 50 diacid or polycarboxylic acid and a diol or a diol. C2-050 polyol, different from the polyester described above, - the ester aliphatic esters resulting from the esterification of an aliphatic hydroxycarboxylic acid ester with a monocarboxylic acid aliphatic; and their mixtures, such as the ester resulting from the esterification reaction of hydrogenated castor oil with isostearic acid in proportions 1 to 1 (1/1) or hydrogenated castor oil monoisostearate, the ester resulting from the esterification reaction of hydrogenated castor oil with isostearic acid in proportions 1 to 2 (1/2) or hydrogenated castor oil diisostearate, the ester resulting from the esterification reaction hydrogenated castor oil with isostearic acid in proportions 1 to 3 (1/3) or hydrogenated castor oil triisostearate, and mixtures thereof.

Among the pasty compounds of plant origin, a mixture of soy sterols and oxyethylenated (5OE) oxypropylene pentaerythritol (5 PO), marketed under the reference Lanolide by the company VEVY, will preferably be chosen. The pasty compound is preferably 1 to 99%, more preferably 1 to 60%, more preferably 2 to 30% and most preferably 5 to 15% by weight of the composition.

The nature and quantity of solid bodies are a function of the desired mechanical properties and textures. The composition may contain from 0 to 50% by weight of waxes, relative to the total weight of the composition and better still from 1 to 30% by weight.

By fillers, it is necessary to include particles of any form, colorless or white, mineral or synthetic, insoluble in the medium of the composition 10 regardless of the temperature at which the composition is manufactured. These fillers serve in particular to modify the rheology or the texture of the composition. The fillers can be mineral or organic of any shape, platelet, spherical or oblong, irrespective of the crystallographic form (for example sheet, cubic, hexagonal, orthorhombic, etc.). Mention may be made of talc, mica, silica, kaolin, polyamide (nylon) powders (Orgasol from Atochem), poly-R-alanine and polyethylene, tetrafluoroethylene polymer powders (Teflon), lauroyl-lysine, starch, boron nitride, polymeric hollow microspheres such as those of polyvinylidene chloride / acrylonitrile such as Expancel (Nobel Industrie), copolymers of acrylic acid (Polytrap 603 from Dow Corning) and silicone resin microbeads (Toshiba Tospearls, for example), elastomeric polyorganosiloxane particles, precipitated calcium carbonate, magnesium carbonate and magnesium carbonate, hydroxyapatite, hollow silica microspheres (Silica Beads from Maprecos), glass or ceramic microcapsules, metal soaps derived from organic carboxylic acids having from 8 to 22 carbon atoms, preferably from 12 to 18 carbon atoms, e.g. Examples are zinc, magnesium or lithium stearate, zinc laurate, magnesium myristate, Polypore L 200 (Chemdal Corporation). Mention may also be made of silica-based fillers such as Aerosil 200 and Aerosil 300; Sunsphare L-31, Sunphare H-31 marketed by Asahi Glass; Chemicelen marketed by Asahi Chemical; silica and titanium dioxide composites such as the TSG series marketed by Nippon Sheet Glass. Finally, mention may be made of polyurethane powders, in particular crosslinked polyurethane powders comprising a copolymer, said copolymer comprising trimethylol hexyl lactone. In particular, it may be a hexamethylene diisocyanate / trimethylol hexyllactone polymer. Such particles are in particular commercially available, for example under the name PLASTIC POWDER D-4000 or PLASTIC POWDER D-8000 from the company TOSHIKI. The filler content may range from 0.01% to 50% by weight, preferably ranging from 0.01% to 30% by weight relative to the total weight of the composition. For the purposes of the present invention, the term "dyestuff" means a compound capable of producing an optical effect when it is formulated in sufficient quantity in a suitable cosmetic medium. The dyestuffs may be present in the composition in a content ranging from 0.01% to 50% by weight, relative to the weight of the composition, preferably from 0.1% to 30% by weight.

The dyestuff may in particular be chosen from dyes, pigments, pearlescent agents and their mixtures.

The dyes are preferably fat-soluble dyes, although water-soluble dyes can be used. Liposoluble dyes are, for example, Sudan Red, D & C Red 17, D & C Green 6, [3-carotene, soybean oil, Sudan Brown, D & C Yellow 11, D & C Yellow C Violet 2, D & C orange 5, yellow quinoline, annatto. They may represent from 0 to 20% of the weight of the composition and better still from 0.1 to 6%. When used, the water-soluble dyes include beetroot juice, methylene blue and may represent from 0.1 to 6% by weight of the composition.

The pigments may be chosen from inorganic pigments, organic pigments, and composite pigments (that is to say pigments based on mineral and / or organic materials). By pigments, it is necessary to include particles of any shape, with an optical effect, mineral or synthetic, insoluble in the medium of the composition regardless of the temperature at which the composition is manufactured. The inorganic pigments may be chosen from metal oxide pigments, titanium dioxide coated mica, bismuth oxychloride coated mica, iron oxide coated titanium mica, ferric blue coated mica-titanium, titanium mica coated with chromium oxide, and mixtures thereof. The metal oxide pigments are, for example, iron oxides, titanium dioxide, zinc oxides, zirconium oxides, cerium oxides, and mixtures thereof. The inorganic pigments are preferably metal oxide pigments.

The pigments may be present in the composition in a content ranging from 0.01% to 25% by weight, relative to the total weight of the composition, and preferably ranging from 1% to 12% by weight, and preferably ranging from 3% to 8% by weight. % in weight.

The organic pigments can be chosen from the pigments and lakes cited in the International Cosmetic Ingredient Dictionary and Handbook, Edition 1997, pages 371 to 386 and 524 to 528, published by The Cosmetic, Toiletry, and Fragrance Association, the content of which is incorporated in this application for reference.

The nacres may be chosen for example from mica coated with titanium oxide, iron oxide, natural pigment or bismuth oxychloride such as colored titanium mica.

The NPY antagonist agents may also be combined in the compositions according to the invention with hydrophilic or lipophilic cosmetic active agents, in particular for the purpose of enhancing the appearance of the lips. This active agent may be chosen in particular from: - agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation (eg collagen synthesis, elastin, etc.), - moisturizing agents, - anti-pollution or anti-agents -radical, - soothing agents, - healing agents, - UV filters.

Proteins stimulating the synthesis of matrix macromolecules Dermal cells, in particular fibroblasts, produce molecules of collagen, elastin and glycoproteins. These molecules confer volume and density to the lips and their outline, as well as their firmness. With the effect of age or even under the effect of UV rays, there is a notable decrease in these molecules and a degradation of collagen and elastin fibers under the effect of collagenase or elastase. This degradation or decrease in the production of these molecules induces a loss of firmness of the lips and their outline, causing in particular the appearance of wrinkles. Among the active agents stimulating the macromolecules of the dermis or preventing their degradation, there may be mentioned those which act: either on the synthesis of collagen, such as extracts of Centella asiatica; asiaticosides and derivatives; ascorbic acid or vitamin C and its derivatives, such as its salts or its esters, in particular 5,6-di-O-dimethylsilylascorbate (sold by Exsymol under the reference PRO-AA), the potassium salt of the dl- alpha-tocopheryl-dlascorbyl-phosphate (sold by Senju Pharmaceutical under the SEPIVITAL EPC reference), magnesium ascorbyl phosphate, sodium ascorbyl phosphate (sold by Roche under the reference Stay-C 50) and ascorbyl glucoside ( sold by Hayashibara); synthetic peptides such as iamin, biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as the soy hydrolyzate marketed by COLETICA under the trade name Phytokine; plant hormones such as auxins and lignans; palmitoyl pentapeptide lysine-threonine-threoninelysine-serine sold in particular under the name MATRIXYL by SEDERMA: dimethyl amino ethanol; Bupleurum Chinensis ricehome extracts, such as those sold under the names PLEURIMINCYL, LIPOCARE by SEDERMA; hydrolyzates of wheat protein acylated in particular by a palmitoyl group, such as that sold under the name LIPACID PVB by SEPPIC; creatine; coenzyme Q10; or on the synthesis of elastin, such as the extract of Saccharomyces cerivisiae sold by LSN under the trade name Cytovitin; and the algae extract Macrocystis pyrifera marketed by SECMA under the trade name Kelpadelie; melibiose; soy protein; or on the synthesis of glycosaminoglycans, such as the product of fermentation of milk with Lactobacillus vulgaris, marketed by BROOKS under the trade name Biomin yogourth; the extract of the brown alga Padina pavonica sold by Alban Müller under the trade name HSP3; and the extract of Saccharomyces cerevisiae available in particular from SILAB under the trade name Firmalift or from LSN under the trade name Cytovitin; C-glycosides and their derivatives as described in EP 1 345 919; or on the synthesis of fibronectin, such as the Salina zooplankton extract marketed by SEPORGA under the trade name GP4G; yeast extract available in particular from ALBAN MÜLLER under the trademark Drieline; and the palmitoyl pentapeptide sold by SEDERMA under the trademark Matrixil; - Or on the inhibition of metalloproteinases (matrix metalloproteinases or MMP) such as more particularly the MMP 1, 2, 3, 9. There may be mentioned: retinoids and derivatives, oligopeptides and lipopeptides, lipoamino acids, malt extract marketed by Coletica under the trade name Collalift; extracts of blueberry or Rosmarinus officinale; lycopene; isoflavones, their derivatives or plant extracts containing them, in particular extracts of soya (marketed for example by ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage; or on the inhibition of serine proteases such as leukocyte elastase or cathepsin G. Mention may be made of: the peptide extract of leguminous seeds (Pisum sativum) sold by LSN under the trademark Parelastyl; heparinoids; and pseudodipeptides such as {2- [acetyl- (3-trifluoromethylphenyl) -amino] -3-methyl-butyrylamino} acetic acid and its derivatives.

Among the active ingredients stimulating fillagrine and keratins, mention may be made in particular of the lupine extract marketed by SILAB under the trademark Structurine; the extract of beech buds Fagus sylvatica marketed by Gattefosse under the trade name Gatuline; and Salina zooplankton extract marketed by SEPORGA under the trade name GP4G.

Preferably, the agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation are chosen from extracts of Centella asiatica, ascorbic acid and its derivatives, peptides extracted from plants, such as commercialized soy hydrolyzate by COLETICA under the trade name Phytokine, the extract of Saccharomyces cerivisiae sold by LSN under the trade name Cytovitin; the extract of the brown alga Padina pavonica sold by Alban Müller under the trade name HSP3; retinoids and derivatives; rosemary extracts; the peptide extract of leguminous seeds (Pisum sativum) marketed by LSN under the trademark Parelastyl; {2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino} acetic acid and its analogs as described in EP 1 292 608, lupine extract; and their mixtures.

Moisturizing agents By "moisturizing agent" is meant: - either a compound acting on the barrier function, in order to maintain the hydration of the stratum corneum, or an occlusive compound. There may be mentioned ceramides, sphingoid-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, R-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4-chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum and lanolin; or a compound directly increasing the water content of the stratum corneum, such as thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, sodium pidolate, serine, xylitol, lactate sodium, glycerol polyacrylate, ectoin and its derivatives, chitosan, oligo- and polysaccharides such as the product marketed under the reference Pentavitin, honey, alginates (in particular the product Sobalg PH 154 marketed by Grindsted), carbonates cyclic N-lauroyl pyrrolidone carboxylic acid or its salts, especially the sodium salt sold under the reference Nalidone, and Na-benzoyl-L-arginine; or a compound that activates the sebaceous glands, such as steroid derivatives (including DHEA, its 7-oxidized and / or 17-alkylated derivatives and sapogenins), methyl dihydrojasmonate, and vitamin D and its derivatives. These compounds may represent from 0.001 to 30%, and preferably from 0.01 to 20%, of the total weight of the composition according to the invention.

Anti-pollution or anti-radical agent By the term "anti-pollution agent" is meant any compound capable of trapping ozone, mono- or polycyclic aromatic compounds such as benzopyrene and / or heavy metals such as cobalt, mercury, cadmium and / or nickel. By "anti-radical agent" is meant any compound capable of trapping free radicals.

As ozone-trapping agents that may be used in the composition according to the invention, mention may be made in particular of vitamin C and its derivatives including ascorbyl glucoside; phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it; olive leaf extracts; tea extracts, especially green tea; anthocyanins; rosemary extracts; phenolic acids, in particular chorogenic acid; stilbenes, in particular resveratrol; sulfur-containing amino acid derivatives, in particular S-carboxymethylcysteine; ergothioneine; N-acetylcysteine; chelating agents such as N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; carotenoids such as crocetin; and various raw materials such as the mixture of arginine, histidine ribonucleate, mannitol, adenosinetriphosphate, pyridoxine, phenylalanine, tyrosine and hydrolysed RNA marketed by Serobiological Laboratories under the trade name CPP LS 2633-12F, the water-soluble fraction of corn marketed by the company SOLABIA under the trade name Phytovityl, the mixture of fumitory extract and lemon extract marketed under the name Unicotrozon C-49 by Induchem, and the mixture of extracts of ginseng, apple, peach, wheat and barley sold by PROVITAL under the trade name Pronalen Bioprotect.

As scavengers for mono- or polycyclic aromatic compounds that can be used in the composition according to the invention, mention may be made in particular of tannins such as ellagic acid; indole derivatives, in particular indol-3-carbinol; tea extracts especially green tea, extracts of water hyacinth or eichornia crassipes; and the water soluble fraction of corn marketed by SOLABIA under the trade name Phytovityl.

Finally, as scavengers for heavy metals that may be used in the composition according to the invention, there may be mentioned in particular chelating agents such as EDTA, the pentasodium salt of ethylenediamine tetramethylene phosphonic acid, and N, N'-bis- ( 3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; phytic acid; chitosan derivatives; tea extracts, especially green tea; tannins such as ellagic acid; sulfur-containing amino acids such as cysteine; water hyacinth (Eichornia crassipes) extracts; and the water soluble fraction of corn marketed by SOLABIA under the trade name Phytovityl.

The anti-radical agents that can be used in the composition according to the invention comprise, in addition to certain anti-pollution agents mentioned above, vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme Q10 or ubiquinone; certain enzymes such as catalase, superoxide dismutase and wheat germ extracts containing it, lactoperoxidase, glutathione peroxidase and quinone reductases; glutathione; benzylidene camphor; benzylcyclanones; substituted naphthalenones; pidolates; phytantriol; gamma-oryzanol; guanosine; lignans; and melatonin.

Soothing agents As soothing agents that can be used in the composition according to the invention, mention may be made of: pentacyclic triterpenes and plant extracts (eg Glycyrrhiza glabra) containing them, such as 13-glycyrrhetinic acid and its salts and / or derivatives thereof ( glycyrrhetinic acid monoglucuronide, stearyl glycyrrhetinate, 3-stearoyloxy glycyrrhetic acid), ursolic acid and its salts, oleanolic acid and its salts, betulinic acid and its salts, plant extracts such as Paeonia suffruticosa and / or lactiflora, Laminaria saccharina, Boswellia serrata, Centipeda cunnighami, Helianthus annuus, Linum usitatissimum, Cola nitida, Epilobium Angustifolium, Aloe vera, Bacopa monieri, salts of salicylic acid and in particular zinc salicylate, canola oil, bisabolol and chamomile extracts, allantoin, EPP Seppic Seperate Sepi EPP (Vitamin E and C diesterphosphoric), unsaturated omega 3 oils such as musk rose, blackcurrant, ecchium, or fish islands, plankton extracts, capryloyl glycine, Seppicalm VG (sodium palmitoylproline and nymphea alba) from Seppic, tocotrienols, piperonal, clove extract , phytosterols, cortisone, hydrocortisone, indomethacin and beta methasone. Thus, the substance P or CGRP antagonists described in EP 0 680 749 and EP 0 723 774, the thermal waters of the Vichy basin or Roche Posay, the extracts of Vitreoscilla filiformis described in patent applications FR 2 279 382, EP 0 765 667, EP 0 876 813 and EP 1 531 158.

Healing Agents Examples of cicatrizing agents include the fern leaf extract marketed under the reference Mamaku Vital Essence by Lucas Meyer, the rice peptides obtained by hydrolysis of rice proteins marketed under the name Nutripeptide by Silab.

UV Filters The compositions according to the invention may further comprise at least one organic photoprotective agent and / or at least one active inorganic photoprotective agent in the UVA and / or UVB (absorbers), which are water-soluble or fat-soluble or insoluble in cosmetic solvents commonly used. The compositions in accordance with the invention may comprise, in addition, other additional organic UV or inorganic UV screening agents active in water-soluble or fat-soluble UVA and / or UVB or insoluble in the cosmetic solvents commonly used. The complementary organic screening agents are chosen in particular from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives, camphor derivatives; triazine derivatives other than those of the invention such as those described in patent applications US 4367390, EP863145, EP517104, EP570838, EP796851, EP775698, EP878469, EP933376, EP507691, EP507692, EP790243, EP944624; benzophenone derivatives; 1,3,13-diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bisbenzoazolyl derivatives as described in patents EP669323 and US 2,463,264; p-aminobenzoic acid derivatives (PABA); methylene bis- (hydroxyphenylbenzotriazole) derivatives as described in US 5,237,071, US 5,166,355, GB2303549, DE 197 26 184 and EP893119; filter polymers and silicone filters such as those described in particular in the application WO-93/04665; dimers derived from α-alkylstyrene such as those described in patent application DE19855649; 4,4-diarylbutadienes as described in Applications EP0967200, DE19746654, DE19755649, EP-A-1008586, EP1133980 and EP133981 and mixtures thereof. As examples of additional organic screening agents, mention may be made of those referred to below under their INCI name: Derivatives of para-aminobenzoic acid: PABA, Ethyl PABA, Ethyl Dihydroxypropyl PABA, Ethylhexyl Dimethyl PABA sold in particular under the name Escalol 507 by ISP, Glyceryl PABA, PEG-25 PABA sold under the name UVINUL P25 by BASF, - Salicylic derivatives: Homosalate sold under the name Eusolex HMS by Rona / EM Industries, Ethylhexyl salicylate sold under the name NEO HELIOPAN OS by HAARMANN and REIMER, Dipropylene glycol Salicylate sold under the name DIPSAL by SCHER, TEA Salicylate, sold under the name NEO HELIOPAN TS by HAARMANN and REIMER, Derivatives of dibenzoylmethane: Butyl Methoxydibenzoylmethane sold in particular under the trade name PARSOL 1789 by HOFFMANN LA ROCHE, Isopropyl Dibenzoylmethane, cinnamic derivatives : Ethylhexyl methoxycinnamate sold in particular under the trade name PARSOL MCX by HOFFMANN LA ROCHE, Isopropyl Meth oxy cinnamate, Isoamyl Methoxy cinnamate sold under the trade name NEO HELIOPAN E 1000 by HAARMANN and REIMER, DEA Methoxycinnamate, Diisopropyl Methylcinnamate, Glyceryl Ethylhexanoate Dimethoxycinnamate - Derivatives of I3,13'-diphenylacrylate: Octocrylene sold in particular under the trade name Uvinul N539 by BASF , Etocrylene, sold in particular under the trade name UVINUL N35 by BASF, - Derivatives of benzophenone: Benzophenone-1 sold under the trade name UVINUL 400 by BASF, Benzophenone-2 sold under the trade name UVINUL D50 by BASF, Benzophenone-3 or Oxybenzone, sold under the trade name UVINUL M40 by BASF, Benzophenone-4 sold under the trade name UVINUL MS40 by BASF, Benzophenone-5, Benzophenone-6 sold under the trade name Helisorb 11 by Norquay, Benzophenone-8 sold under the trade name Spectra-Sorb UV-24 by American Cyanamid, Benzophenone-9 sold under the trade name UVINUL DS-49 by BASF, Benzophenone-12, Di ethylamino Hydroxybenzoyl Hexyl Benzoate sold under the trade name UVINUL A PLUS by BASF, - Derivatives of benzylidene camphor: 3-Benzylidene camphor manufactured under the name MEXORYL SD by CHIMEX, 4-Methylbenzylidene camphor sold under the name EUSOLEX 6300 by MERCK, Benzylidene Camphor Sulfonic Acid manufactured under the name MEXORYL SL by CHIMEX, Camphor Benzalkonium Methosulfate manufactured under the name MEXORYL SO by CHIMEX, Terephthalylidene Dicamphor Sulfonic Acid manufactured under the name MEXORYL SX by CHIMEX, Polyacrylamidomethyl Benzylidene Camphor manufactured under the name MEXORYL SW by CHIMEX, - Derivatives of phenyl benzimidazole: Phenylbenzimidazole Sulfonic Acid sold in particular under the trade name Eusolex 232 by Merck, Disodium Phenyl Dibenzimidazole Tetrasulfonate sold under the trade name NEO HELIOPAN AP by HAARMANN and REIMER, - Triazine derivatives: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine sold under the business name TINOSORB S by CIBA GEIGY, Ethylhexyl triazone sold in particular under the trade name UVINUL T150 by BASF, Diethylhexyl Butamido Triazone sold under the trade name UVASORB HEB by SIGMA 3V, - Derivatives of phenyl benzotriazole: Drometrizole Trisiloxane sold under the name Silatrizole by Rhodia Chimie Methylene bis-Benzotriazolyl Tetramethylbutylphenol, sold in solid form under the trade name MIXXIM BB / 100 by FAIRMOUNT CHEMICAL or in micronized form in aqueous dispersion under the trade name TINOSORB M by CIBA SPECIALTY CHEMICALS, - Anthranilic derivatives: Menthyl anthranilate sold under the trade name 25 commercial NEO HELIOPAN MA by HAARMANN and REIMER, - Imidazoline derivatives: Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate, - Derivatives of benzalmalonate: Polyorganosiloxanes containing benzalmalonate function such as Polysilicone-15 sold under the trade name PARSOL SLX 30 by HOFFMANN LA ROCHE - Derivative 4,4-diarylbutadiene: -1,1-dicarboxy (2,2'-dimethylpropyl) -4,4-diphenylbutadiene - Benzoxazole derivatives: 2,4-bis- [5-1 (dimethylpropyl) benzoxazole; 2-yl- (4-phenyl) imino] -6- (2-ethylhexyl) imino-1,3,5-triazine sold as Uvasorb K2A by Sigma 3V and mixtures thereof. Preferred complementary organic UV screening agents are chosen from: ethylhexyl salicylate, homosalate, ethylhexyl methoxycinnamate, butyl methoxydibenzoylmethane, octocrylene, phenylbenzimidazole sulphonic acid, 40 disodium phenyl dibenzimidazole tetrasulfonate, benzophenone-3, benzophenone-4, benzophenone-5, 2- ( N-hexyl 4-diethylamino-2-hydroxybenzoyl) benzoate, 4-Methylbenzylidene camphor, Terephthalylidene Dicamphor Sulfonic Acid, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Ethylhexyl triazone, Diethylhexyl Butamido Triazone, Methylene bis-Benzotriazolyl Tetramethylbutylphenol, Drometrizole Trisiloxane, Polysilicone-15 1,1-Dicarboxy (2,2'-dimethyl-propyl) -4,4-diphenylbutadiene, 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] 6- (2-ethylhexyl) imino-1,3,5-triazine and mixtures thereof.

The inorganic complementary photoprotective agents are chosen from pigments and even more preferably nanopigments (average size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) of metal oxides treated or untreated, for example nanopigments of titanium oxide (amorphous or crystallized in rutile and / or anatase form), iron, zinc, zirconium or cerium.

The treated nanopigments are pigments which have undergone one or more surface treatments of a chemical, electronic, mechanochemical and / or mechanical nature with compounds as described, for example, in Cosmetics & Toiletries, February 1990, Vol. 105, p 53-64, such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron, or aluminum salts. fatty acids, metal alkoxides (titanium or aluminum), polyethylene, silicones, proteins (collagen, elastin) alkanolamines, silicon oxides, metal oxides, sodium hexametaphosphate, alumina or glycerine. The nanopigments treated may more particularly be titanium oxides treated with: silica and alumina, such as the products Microtitanium Dioxide MT 500 SA and Microtitanium Dioxide MT 100 SA from TAYCA, and the products Tioveil Fin, Tioveil OP, Tioveil MOTG and TIOVEIL IPM from the company TIOXIDE, aluminum alumina and stearate such as the Microtitanium Dioxide MT 100 T product from TAYCA, aluminum alumina and laurate such as the product Microtitanium Dioxide MT 100 S from TAYCA, iron oxides and iron stearate, such as the product Microtitanium Dioxide MT 100 F from TAYCA, silica, alumina and silicone, such as Microtitanium Dioxide MT 100 products. SAS, Microtitanium Dioxide MT 600 SAS and Microtitanium Dioxide MT 500 SAS from the company TAYCA, sodium hexametaphosphate such as the product Microtitanium Dioxide MT 150 W TAYCA company, - octyltrimethoxysilane such as the T-805 product of the company Degussa, 40 - alumina and stearic acid such as the product UVT-M160 Kemira company - alumina and glycerin such that the UVT-M212 product from the company KEMIRA, - alumina and silicone such as the product UVT-M262 from the company KEMIRA.

Other nanopigments of titanium oxide treated with a silicone are preferably TiO 2 treated with octyl trimethyl silane and whose average elementary particle size is between 25 and 40 nm, such as that sold under the trade name "T 805 "by the company Degussa Silices, the TiO 2 treated with a polydimethylsiloxane and whose average elementary particle size is 21 nm, such as that sold under the trade name" 70250 Cardre UF TiO2SI3 "by CARDRE, TiO2 anatase / rutile treated with a polydimethylhydrogensiloxane and whose average elementary particle size is 25 nm, such as that sold under the trade name "MICRO TITANIUM DIOXIDE USP GRADE HYDROPHOBIC" by the company COLOR TECHNIQUES.

Uncoated titanium oxide nanopigments are for example sold by the company Tayca under the trade names "MICROTITANIUM DIOXIDE MT 500 B" or "MICROTITANIUM DIOXIDE MT600 B", by the company DEGUSSA under the name "P 25", by the WACKHER company under the name "transparent titanium oxide PW", by MIYOSHI KASEI under the name "UFTR", by TOMEN under the name "ITS" and by the company TIOXIDE under the name "TIOVEIL AQ".

The uncoated zinc oxide nanopigments are, for example, those marketed under the name "Z-cote" by the company Sunsmart; those marketed under the name "Nanox" by Elementis; those marketed under the name "Nanogard WCD 2025" by Nanophase Technologies.

The coated zinc oxide nanopigments are, for example, those sold under the name "Zinc Oxide CS-5" by the company Toshibi (ZnO coated with polymethylhydrogenosiloxane); those marketed under the name "Nanogard Zinc Oxide FN" by Nanophase Technologies (as a 40% dispersion in Finsolv TN, C12-C15 alcohol benzoate); those marketed under the name "DAITOPERSION ZN-30" and "DAITOPERSION Zn-50" by the company Daito (dispersions in cyclopolymethylsiloxane / polydimethylsiloxane oxyethylenated, containing 30% or 50% of zinc nano-oxides coated with silica and the polymethylhydrogensiloxane); those sold under the name "NFD Ultrafine ZnO" by the company Daikin (ZnO coated with perfluoroalkyl phosphate and a copolymer based on perfluoroalkylethyl dispersed in cyclopentasiloxane); those marketed under the name "SPD-Z1" by Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane); those marketed under the name "Escalol Z100" by the company ISP (ZnO treated alumina and dispersed in the mixture methoxycinnamate ethylhexyl / copolymer PVP-hexadecene / methicone); those marketed under the name Fuji ZnO-SMS-10 by the company Fuji Pigment (ZnO coated with silica and polymethylsilsesquioxane); those marketed under the name "Nanox Gel TN" by Elementis (ZnO dispersed at 55% in C12-C15 alcohols benzoate with hydroxystearic acid polycondensate).

Uncoated cerium oxide nanopigments are sold under the name "COLLOIDAL CERIUM OXIDE" by the company RHONE POULENC.

The uncoated iron oxide nanopigments are for example sold by ARNAUD under the names "NANOGARD WCD 2002 (FE 45B)", "NANOGARD IRON FE 45 BL AQ", "NANOGARD FE 45R AQ," NANOGARD WCD 2006 (FE 45R) ", or by the company MITSUBISHI under the name" TY-220 ".

The coated iron oxide nanopigments are for example sold by ARNAUD under the names "NANOGARD WCD 2008" (FE 45B FN), "NANOGARD WCD 2009 (FE 45B 556)", "NANOGARD FE 45 BL 345", "NANOGARD FE 45 BL", or by the company BASF under the name "OXIDE OF CLEAR IRON".

Mention may also be made of mixtures of metal oxides, in particular titanium dioxide and cerium dioxide, including the titanium dioxide and silica-coated cerium dioxide equivalent mixture sold by the company IKEDA under the name "SUNVEIL" A ", as well as the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone such as the product" M 261 "sold by the company KEMIRA or coated with alumina, silica and glycerin such as the product "M 30 211" sold by KEMIRA.

The nanopigments may be introduced into the compositions according to the invention as such or in the form of a pigment paste, that is to say in a mixture with a dispersant, as described for example in GB-A-2206339.

The additional photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.01% to 20% by weight relative to the total weight of the composition, and preferably ranging from 0.1% to 10% by weight relative to the total weight of the composition. relative to the total weight of the composition.

The care and / or makeup composition of the lips may be in the form of a lipstick stick, a liquid gloss, a lipstick paste, a pencil 40 for the outline of the lips. lips, a lip balm, a lip varnish otherwise known as lip lacquer.

The lip balm will be especially intended to protect the lips from cold and / or sun and / or wind. The liquid gloss, also called liquid lipstick or lip gloss, is a fluid product intended to be applied to the lips and packaged for example in a container provided with an applicator, this applicator comprising a gripping member which also serves as a closure cap of the container, and an applicator element.

According to a particular embodiment of the invention, said natural repulping agent and / or stimulating the coloring of the lips used in the compositions of the invention is associated with at least one makeup agent with an optical effect of volume.

This makeup agent with an optical volume effect is intended to reinforce the volume effect obtained by the first agent and / or to give the composition applied to the lips an immediate volumizing optical effect relayed over time by the natural volumizing effect. mediated by the first agent. The presence of the first agent in the composition also makes it possible to reduce the normally effective concentrations of the second agent in order to obtain the desired effect on the volume and / or color of the lips, so as to favor the natural appearance of the makeup.

As an optical volume-enhancing makeup agent, for example, goniochromatic pigments, reflective particles and mixtures thereof may be used.

By goniochromatic pigment is meant in particular a pigment capable of producing different colors depending on the incidence of light and the angle of observation. Preferably, the goniochromatic pigments are goniochromatic pigments with an interferential multilayer structure. In particular, it is possible to use the goniochromatic pigments described in application EP 1 382 323. The multilayer structure of the goniochromatic pigments may comprise at least two layers, each layer, independently or otherwise of the other layer (s). , being made of at least one material selected from the group consisting of the following materials: MgF 2, CeF 3, ZnS, ZnSe, Si, SiO 2, Ge, Te, Fe 2 O 3, Pt, Va, Al 2 O 3, MgO, Y 2 O 3, S 2 O 3, SiO , HfO 2, ZrO 2, CeO 2, Nb 2 O 5, Ta 2 O 5, TiO 2, Ag, Al, Au, Cr, Cu, Rb, Ti, Ta, W, Zn, MoS 2, cryolite, alloys, polymers and their combinations. By way of example, these pigments may be the pigments of silica / titania / tin oxide structure marketed under the trademark XIRONA MAGIC by MERCK, and the silica / brown iron oxide structural pigments marketed under the name XIRONA INDIAN. SUMMER by MERCK and the silica / titanium oxide / mica / tin oxide structural pigments marketed under the name XIRONA CARRIBEAN BLUE by MERCK. One can also mention Sicopearl Fantastico manufactured or marketed by BASF, Colorstream manufactured or marketed by MERCK, Chromaflair manufactured or marketed by FLEX, Xirallic manufactured or marketed by MERCK; INFINITE COLORS pigments from SHISEIDO. By way of example of pigments with a polymeric multilayer structure, mention may be made of those marketed by 3M under the name COLOR GLITTER. As liquid crystal goniochromatic particles, it is possible, for example, to use those sold by CHENIX as well as those marketed under the name HELICONE HC by WACKER.

In general, the structure is composed of alternating layers of low optical index and high optical index.

The goniochromatic pigments may be present in the composition according to the invention in a content ranging from 0.01 to 50% by weight, relative to the total weight of the composition, preferably from 0.1 to 30% by weight, and better from 0.3 to 20% by weight.

By reflecting particles is meant in particular particles whose size, structure, and surface state allow them to reflect the incident light with sufficient intensity to be able to create on the surface of the claimed composition, when the latter is applied on the medium to make up, points of highlighting visible with the naked eye, that is to say more luminous points which contrast with their environment while appearing to shine. For example, the particles comprising a natural or synthetic substrate, at least partially coated with a layer of at least one metal, the particles with a synthetic substrate at least partially coated with at least one layer of a metal compound and in particular of a metal oxide, the particles formed of a stack of at least two layers with different refractive indices, in particular two layers of polymers, and the particles of metal oxides. The metal may be selected for example from Ag, Au, Cu, Al, Ni, Sn, Mg, Cr, Mo, Ti, Pt, Va, Rb, W, Zn, Ge, Te, Se and their alloys. Ag, Au, Al, Zn, Ni, Mo, Cr, Cu and their alloys (eg, bronzes and brasses) are preferred metals. By way of example, platelet-shaped silver-coated glass substrate particles sold under the name MICROGLASS METASHINE REFSX 2025 PS can be used by TOYAL; or particles with a glass substrate coated with a nickel / chromium / molybdenum alloy sold under the name CRYSTAL STAR GF 550, GF 2525 by the same company.

The reflective particles, whatever their shape, may also be chosen from particles with a synthetic substrate at least partially coated with at least one layer of at least one metal compound, in particular a metal oxide, chosen for example from oxides titanium, in particular TiO2, iron, in particular Fe2O3, tin, chromium, barium sulfate and the following compounds: MgF2, CrF3, ZnS, ZnSe, SiO2, Al2O3, MgO, Y2O3, SeO3, SiO, HfO2, ZrO2 , CeO 2, Nb 2 O 5, Ta 2 O 5, MoS 2 and mixtures or alloys thereof. By way of example of such particles, mention may be made, for example, of particles comprising a synthetic mica substrate coated with titanium dioxide, or glass particles coated with either brown iron oxide or titanium oxide, tin oxide or a mixture thereof such as those sold under the trade name REFLECKS by ENGELHARD. Also suitable for the invention are the pigments of the METASHINE 1080R range marketed by NIPPON SHEET GLASS CO. LTD. These pigments, more particularly described in the patent application JP 2001-11340, are C-GLASS glass flakes comprising 65 to 72% SiO 2, coated with a titanium oxide layer of rutile type (TiO 2). These glass flakes have an average thickness of 1 micron and an average size of 80 microns is a ratio average size / average thickness of 80. They have blue, green, yellow or silver-tone reflections depending on the thickness of the layer of TiO2. It is also possible to mention particles having a size of between 80 and 100 μm, comprising a synthetic mica substrate (fluorophlogopite) coated with titanium dioxide representing 12% of the total weight of the particle, sold under the name PROMINENCE by NIHON KOKEN.

The reflective particles may be present in the composition by being dispersed homogeneously, for example at a content ranging from 0.1 to 20% relative to the total weight of the composition, preferably from 1 to 15% by weight, and better still 1 to 10% by weight, for example about 2%, especially for a composition intended to be applied to the lips.

The composition may be in any galenic form suitable for topical application to the lips, in particular one of those described previously in the description.

Examples of such compounds are described above.

The examples given below are presented for illustrative and non-limiting purposes of the invention. EXAMPLES

Example 1 - Vasoconstrictor effect of NPY 10 lipid biopsies from different donors were maintained in survival in a D-MEM medium (37 ° C 5% CO2). The lips are incubated with or without NPY in the survival medium for 4 hours.

The biopsies are then fixed in Bouin's fluid and then undergo a classic histological treatment hemalun / eosin. On ten microscope fields (* 40) the percentage of vessels with visible light is established. The average surface of the light is quantified. % of vessels with light Aire (pm2) visible Control 92 + - 12 229 + -124 NPY, 10 p M 73 * + - 20 125 * + -68 * p <0.05 (Student paired t test) NPY reduced statistically significantly the number of dilated vessels. It also reduces the diameter of vessels still dilated.

This clearly demonstrates the vasoconstrictor effect of NPY on the vessels of the lips. Example 2 - Compositions Lip balm - BIBP3226: (n (R) -N2- (diphenylacetyl) -N - [(4-hydroxyphenyl) methyl] argininamide) 0.25% - Carnauba wax 12.75% - Oxypropylenated lanolin wax (5 propylene oxides) 15.00% - castor oil qs 15 20 100% 0/0 After melting the carnauba and lanolin waxes at 100 ° C., the castor oil containing the After cooling down (temperature below or equal to 40 ° C.), the mixture is mixed and poured into a suitable mold.

Claims (14)

REVENDICATIONS1. Cosmetic use of an effective amount of at least one neuropeptide Y (NPY) antagonist agent chosen from chemical, peptide or non-peptide molecules or an extract chosen from extracts obtained by extracting a spongia Orina sp., Gray or Gellius sp., fermentations extracts of strains of Aspergillus, extracts obtained by fermentation of Actinomycetaceae strains and extracts obtained from Cynara scolymus, in a composition containing a physiologically acceptable medium, to improve the appearance of lips by increasing the volume and / or natural coloring of the lips. 2. Use according to claim 1, to increase the size and / or thickness of the lips and / or reshape and / or smooth and / or give them a more inflated or fleshy appearance. 3. Use according to claim 1 for increasing the naturally rosy color of the lips. 4. Use according to any one of the preceding claims, characterized in that said agent is chosen from: 1. The compounds of formula (I) ## STR1 ## wherein Art represents naphthyl, phenyl, quinolyl or isoquinolyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy, hydroxyl or (C1-C4) dialkylamino; Ar 2 represents phenyl or thienyl, optionally substituted with Cl, F, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or hydroxyl; R 1, R 2 and R '2 independently of one another represent hydrogen, (C 1 -C 4) alkyl or R 1 represents nothing and N is bonded to Ar 2 and, optionally, R 2 and R' 2 form a double bond, or R1 or R2 is bonded to Ar2 and represents (C1-C3) alkylene; R3 and R4, which are identical or different, represent hydrogen, (C1-C4) alkyl or form, with the nitrogen atom to which they are bonded, a (C5-C7) saturated heterocycle chosen from pyrrolidine, piperidine and hexahydroazepine; 3 R Ar2 N-Q3 - CSNiZ; Q1 ~ (I) Q2-Z1 represents (C1-C12) alkylene interrupted or optionally substituted with (C5-C7) cycloalkyl or phenyl; Q 1 represents methyl, amino, (C 1 -C 4) alkoxycarbonylamino, (C 1 -C 4) alkylamino, di (C 1 -C 4) alkylamino, pyrrolidinyl, piperidino, morpholino, piperazinyl, (C 1 -C 4) alkyl-4-piperazinyl, amidino, (C1-C4) alkylamidino, guanidino, (C1-C4) alkylguanidino, pyridyl, imidazolyl, pyrimidinyl, indolyl, hydroxy, (C1-C4) alkoxy, (C2-C8) alkoxycarbonyl, N- [amino-C1-C4] alkyl ] -N - [(C1-C4) alkyl] amino, carbamoyl or phenyl optionally substituted with Cl, F, (C1-C4) alkyl, (C1-C4) alkoxy or hydroxyl; Q2 represents hydrogen or (C1-C4) alkyl; - Q3 represents hydrogen or (C1-C4) alkyl or Q1 and Q3 are linked to form a heterocycle and together represent (C2-C3) alkylene while Z1 represents nothing, in the form of pure enantiomers or their mixtures in Any proportions, as well as their addition salts with acids, II - The analogues of raloxifene, III - The phenylsulfonylquinolines of formula (IV): R1yO R2y in which Ry is an optionally substituted aryl, - R'y is -NO2 , Wherein R3 is H, alkyl or aryl, -SO2R3y wherein R3y is as defined above, or R3yO wherein R3y is as defined above, or C101R10 in which wherein R3y is as defined above, - R2y is -NH2, -OH or ùSH and its salts, IV - Bénextramine and its analogues, V - Inositol phosphate derivatives selected from the specific isomers of inositoltriphosphate and inositol monophosphate in acid form and its salts, I! Compounds of formula (V): wherein: Ar 'is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each optionally mono- or disubstituted with halogen, hydroxy, or lower straight or branched chain alkyl having 1 to 6 carbon atoms; - A ', W', X ', Y', and r are identical or different and represent a hydrogen, a halogen, a hydroxy, a linear or branched lower alkoxy chain having 1 to 6 carbon atoms; - R'1 and R'2 are identical or different and represent a hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; R'3 and R'4 are identical or different and represent a hydrogen, a linear or branched lower alkyl chain having 1 to 6 carbon atoms; and R'9 represents hydrogen, a straight or branched lower alkyl chain having 1 to 6 carbon atoms, or phenyl; and their salts, VII - The compounds of formula (VI): Ta-Za-N R 'a- (R2a C R3a) -CO-Ya- (CH 2) na- Ra in which - na represents 0, 1, 2 , 3, 4, or 5; Ra represents a hydrogen atom, a phenyl or naphthyl group optionally mono- or disubstituted with an identical or different substituent; - Ria is a hydrogen aroma, a linear or branched (C1-C10) alkyl group, a cycloalkyl group having from 3 to 7 carbon atoms, a phenyl group optionally substituted by a hydroxy or hydroxyalkyl group, or a phenylmethyl group optionally substituted on the phenyl part by a hydroxy or hydroxyalkyl group, - R2a is a non-branched (C1-05) alkyl substituted in the omega position by an amino or alkylamino group protected by an amino group protecting group, by a dialkylmino group, N- alkylbenzylamino, aminocarbonyl, aminocarbonylamino, aminoethylimine, aminoiminomethyl, amino (hydroxyimino) methyl, amino (alkoxyimino) methyl, amino (nitroimino) methyl, 46 [amino (nitroimino) methyl] amino, amino (cyanimino) methyl, [amino (cyanimino) methyl ] amino, [(alkylamino) iminomethyl] amino, [(alkylamino) (alkylimino) methyl] amino, [amino (alkylimino) methyl] amino, 2-aminimidazol-1-yl, (5-amino-4H-1, 2,4-triazol-3-yl) amino, (5-amino-4H-1,2,4-triazol-3-yl) m thylamino, (3-amino-1,2,4-oxadiazol-5-yl) amino or (5-amino-1,2,4-oxadiazol-3-yl) amino or by imidazol-4-yl, imidazol 2-yl, 1-methyl-imidazol-2-yl, imidazol-2-yl-amino, imidazol-2-ylmethylamino, (4,5-dihydro-1H-imidazol-2-yl) amino optionally substituted on carbon with one or two methyl groups, or a phenyl or phenylmethyl group optionally substituted on the aromatic rings by cyano, iminomethylamino, cyaniminomethylamino, (methylamino) methyl idenamino, aminoiminomethyl, amino- (hydroxyimino) methyl, amino (alkoxyimino) methyl, hydrazinoiminomethyl, amino (cyanimino) methyl or guanidino or with an imidazol-2-yl, 1-methyl-imidazol-2-yl, 4,5-dihydro-1H-imidazol-2-yl group optionally substituted on the atoms of carbon with one or two methyl groups, wherein in the aminoiminomethyl, amino (hydroxyimino) methyl and guanidino groups mentioned in the definition of R2a above, one or more atoms hydrogen atoms connected to the nitrogen atom, independent of each other, can be replaced by alkyl groups or in which two hydrogen atoms connected to different nitrogen atoms can be replaced by an alkyl bridge having from 2 to 4 carbon atoms and for which the hydrogen atom of a group HN <, HN = or H2N in the residue R2a may be substituted by an alkoxycarbonyl group having from 2 to 7 carbon atoms, by a phenylalkoxycarbonyl group in which the alkyl is (C1-C6), phenyloxycarbonyl, R15a-CO-O- (R16aCR17a) -O-CO or (R18aO) PO (OR19a) wherein R15a is a group ( C1-C15) alkyl, a (C3-C7) cycloalkyl group, a phenyl group or a phenylalkyl group in which the alkyl is (C1-C3), R16a and R17a, identical or different, represent a hydrogen atom , a (C1-C6) alkyl group, or one of the radicals R16a and R17a represent a (C3-C7) cycloalkyl group or a phenyl group R18a and R19a, which may be identical or different, represent a hydrogen atom, (C1-C4) alkyl groups, benzyl or phenyl groups, R3a is a hydrogen atom, a (C1-C7) alkyl group or a (C 4 -C 7) cycloalkyl group, Ta is a hydrogen atom, a phenyl group or a 5-membered heteroaryl group connected by a carbon or nitrogen atom and comprising a nitrogen, oxygen or of sulfur optionally substituted by an alkyl group, or comprising a nitrogen atom optionally substituted with an alkyl group and an additional sulfur, oxygen or nitrogen atom, or else when Za represents a bond, Ta is a group protecting an amino group or the residues (T1aT2aUa) - (CH2) m- or T3aO-, in whichT1a to T3a, identical or different, are phenyl groups or 6-membered heteroaryl groups linked by carbon atoms which, depending on the case, comprise one or two nitrogen atoms, hetero groups 5-membered aryls linked by carbon or nitrogen atoms, comprising a nitrogen atom optionally substituted by an alkyl, sulfur or oxygen group, or comprising a nitrogen atom optionally substituted by an alkyl group and a nitrogen, sulfur or additional oxygen atom, in which a 1,4-butadienylene bridge may be formed between two adjacent carbon atoms of the 5- or 6-membered heteroaryl groups mentioned above in the definition of residues Ta; the bicyclic aromatic or heteroaromatic rings thus formed may also be bonded to a carbon atom of the 1,4-butadienylene group and, moreover, both the phenyl groups, the 5 or 6-membered heteroaryl groups and the bicyclic aromatic or heteroaromatic rings may be mono or disubstituted on the carbon skeleton by fluorine, chlorine, bromine or iodine atoms or by cyano, hydroxy, amino, dimethylamino, diethylamino, N-ethyl-methylamino, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, acetylamino groups propionylamino, methanesulfonylamino, methansulfonyloxy, phenyl, phenylmethoxy, 2-phenylethoxy, alkyl, or alkoxy or trisubstituted with an amino or hydroxy group and two chlorine or bromine atoms or with a hydroxy group and two alkyl or alkoxy groups, the substituents being same or different, and the alkyl and alkoxy parts mentioned above comprising from 1 to 4 carbon atoms, hydrogen atoms, (C1-C12) alkyl groups, cycloalkyl groups having 3 to 10 carbon atoms, bicycloalkyl or tricycloalkyl groups having 6 to 12 carbon atoms or T1a and T2a together represent a linear chain C 1 -C 7 alkylene group, Ua is the> CH group, in which the hydrogen atom may be replaced by an alkyl, phenyl, hydroxy, alkoxy, alkanoyloxy, alkoxycarbonyl aikanoylamino group, in which the alkyls or the abovementioned alkoxys can comprise in the case of 1 to 3 carbon atoms and the alkanoyls mentioned above can comprise 2 or 3 carbon atoms, or the> CHCH 2 - group or the nitrogen atom, m represents 0, 1, 2, or 3 or Ta is a group (T'aT2aUa) - (CH2) ma in which T'a, T2a, Ua and ma are as defined above with the difference that mono- or bicyclic aromatic or heteroaromatic rings mentioned above for T1a and T2a are between them by a bond, a -CH2-, -C (CH3) 2-, -CH2CH2-, -CH = CH- or -NHCO- bridge, Ya is an oxygen atom or a group -NR4a, wherein R4a takes the above-mentioned definition 40 of Ria, the residues of Ria and R4a may be the same or different, and Za is a single bond defined by a -CO-, -CH2-, -SO-, or -SO2 group and, unless otherwise stated, the alkyl and alkoxy moieties mentioned above may comprise from 1 to 3 carbon atoms, and tautomers, diastereomers, enantiomers, mixtures and salts thereof, VIII. NH RäN (CH₂) m "NH NHR R₂ / N- (CH₂) n ,. in which R "1 represents a phenyl group which is unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl group or a pyridinyl ring which is unsubstituted or substituted by one or two halogen atoms, a (Cl-C3) group ) alkyl or a (C1-C3) alkoxy group, - R "2 represents a hydrogen atom, a (C1-C3) alkyl group, a phenyl group optionally substituted by one or two halogen atoms or by a group ( C1-C3) alkyl or by a (C1-C3) alkoxy group, a benzyl or heteroaryl group unsubstituted or substituted by one or two halogen atoms or a (C1-C3) alkyl or (C1-C3) alkoxy group wherein n "is 1, 2, 3 or 4 or wherein R" is defined by the formula: wherein R "3 is a pyridinyl ring which is unsubstituted or substituted by one or two halogen atoms, a (C1-C3) alkyl or (C1-C3) alkoxy group, R "4 represents a hydrogen atom or a phenyl group optionally substituted with one ortwo halogen atoms or a (C1-C3) alkyl group or a (C1-C3) alkoxy group, R "represents a hydrogen atom or a methyl or hydroxy group and Z" represents a single bond, a oxygen atom, or a sulfur atom and p "represents 1, 2 or 3, m" represents 1, 2 or 3 and R "O represents a hydrogen atom or a methyl group, as well as their pharmaceutically acceptable salts, (VII) wherein R "is defined by the formula: R" 50IX - Dihydropyridines of formula x R5 Bx Zx (CH2) nx / (VIII) wherein - R1x is lower alkyl; R2x and R3x are independently selected from cyano and lower alkyl; R4x is selected from -CO2R1x, cyano and WhereN - CH3 - R5x is selected from hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyloxy and lower alkoxy; - Bx is -NH- or a covalent bond; Nx represents an integer of 2 to 5 and - Zx is selected from the group consisting of: RI Nù ~ And the solid or dotted lines representing a single or double bond, as well as their addition salts or solvates, X Compounds of formula: Tyr-Pro-Ser-Lys-Pro-Asp-D-Cys-N H- (C H2) S-CO-Xxx2-Arg-Cys-Tyr-Xxx3-Ala-Leu-Arg-His -Tyr-Xxx4-Asn-Leu-Xxx5-Thr-Arg-Ile-Arg-Tyr-Tc (IX) in which - Xxx2 and Xxx3 are Ser or Ala, - Xxx4 and Xxx5 are Leu, Ile, Met, Nle ( Norleucine) or Val - Tc is OH, O (C1-C4) alkyl, NH2 or NH (C1-C4) alkyl, s is an integer from 1 to 11, and their salts, XI - Compounds of formula Zb -Ak1 -Bk2-B Pk3-Dk4-Ek5-Fks-Gk, -D P-Thr-B p'-Glu-B P "-KN H in which k1, k2, k3, k4, k5, k6 and k7 represent zero or 1, their sum being at least 1, A is Phe or Tyr, B is Pro, Ser, Ala, Gly, Abu, Cys, Pro-Ser, Cys-Ser, Ala-Ser, Gly-Ser, Abu- Ser or Pro-Ala, Abu being 2-aminobutyric acid, BP, BP 'and BP "are amino acids s with a basic side chain; D is Pro or Cys; E 25 is NH- (CH 2) t-CO, t being 0-10; F is Cys, Abu Gly or Ala; G is Ile-Asn, Leu-Asn, Val-Asn or Asn; DP is the residue of a dipeptide formed by lipophilic amino acids; K is Phe or Tyr; Zb is hydrogen, an amino-protecting group or a benzyl, (C 2 -C 10) acyl or (C 1 -C 5) alkyl group and in which two Cys residues may be linked by a disulfide bridge, as well as their salts; Cyclic or linear compounds of formula (XI) (XXXa-XXXb-XXXc-XXXd-XXXe-XXXf-XXXg-Xxxh-Xxx; -XXxj), in which Xxxa, Xxxb, Xxx, and Xxxj may not exist, or else Xxxa is P1 or Cys; Xxxb is Cys, P1 or one or two amino acids; Xxx, is P1, Cys, Ser, Thr, Ala, or Gly; Xxxd is R1, Cys, Ser, Thr, Ala or Gly; Xxxe is Leu, Ile, Val or Nle; Xxxg is Arg, Lys or His; Hxxg is Arg, Lys, His, Val, Leu, Ile or Nle; Xxxh is Tyr, Phe, Trp, His, Lys or Arg; xxx; represents an NH 2 group or an ester group or one or two amino acids; Xxxj is Cys or P2; P1 is hydrogen or a P-CO group where P is hydrogen, a glycosyl, nucleosyl or lipolyl radical or a (C1-C20) alkyl group, optionally containing double bonds and substituents chosen from halogens and the group NO2, NH2, OH, sulfo, phospho, 5carboxy and alkyl; P2 is NP12P13 or OP14 wherein P12 and P13 are hydrogen or alkyl, cycloalkyl, N-glycosyl, N-lipolyl, aralkyl or aryl, optionally substituted with halogen or with NO2, NH2, OH, sulfo, phospho, carboxy or alkyl; and P14 represents hydrogen or an alkyl, cycloalkyl, aralkyl, -O-glycosyl, -O-lipolyl, aralkyl or aryl group, optionally substituted by a halogen or a NO2, NH2, OH, sulfo, phospho, carboxy or alkyl, with the limitation that when Xxxb does not exist or represents Cys or P1, then Xxxa is non-existent, when Xxxd is Cys or PI, then Xxxc is non-existent, when Xxxi is NH2 or an ester, then Xxxi is non-existent, XIII - Compounds of formula H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu- (XII) Asp-Ala-Pro-Ala-G Iu-Asp-Xxx6-Ala-Arg-Tyr- Tyr-Ser-Ala-Leu-Arg-His-Tyr-I-Asn-Leu-I-Thr-Arg-Xxxr-Xxxe-L 1- (CH2) Z-P3 wherein z is 0.1 or 2 Xxx6 is Met or Leu; Xxx7 is Glu, (R) -Glu, Pro or (R) -Pro; Xxx8 is Arg, (R) -Arg or (R, S) -Arg; LI is O or NP ', P' being H or alkyl; and P3 is phenyl or naphthyl unsubstituted or substituted with one or two F, Cl, Br, alkyl, phenyl, OH, (phenyl) alkoxy, alkylcarbonyl, NH2 (optionally substituted by one or two alkyls), alkylsufonyl, alkyl or alkoxycarbonylamino, COOH, alkoxycarbonyl, NH 2 CO (optionally substituted with one or two alkyls), alkylcarbonyloxy, alkylsulphonyloxy, CH 2 OH, 1- or 2-hydroxyethyl, (alkyl) aminosulfonyl, cyanamino, aminocarbonylamino (optionally substituted with one or two alkyls) or NH2C (= N.CN) NH; a 5-membered aromatic heterocycle containing oxygen, sulfur or nitrogen, an imino group or an imino group containing oxygen, sulfur or nitrogen; a 6-membered aromatic heterocycle with one or two nitrogen atoms; said heterocycles may be C-substituted by (C 1 -C 6) alkyl or phenylalkyl and optionally fused to benzene and optionally also substituted by F, Cl, Br, (C 1 -C 6) alkyl, alkoxy, OH, phenyl, NO 2, NH 2 (optionally substituted by one or two alkyls or an alkanoyl), CN, COOH, alkoxycarbonyl, NH 2 CO (optionally substituted by one or two alkyls), CH 2 F, CHF 2, CF 3, alkanoyl or NH 2 SO 2 (optionally substituted with one or two alkyls) or with two F, Cl, Br, methyl, methoxy or OH; a phenyl group substituted by a [1,5-dihydro-2,4- (3H) -dioxoimidazol-3-yl] alkyl group or by a [3,5-dihydro-4H) -dioxo-3H-group 2,4-triazol-4-yl] alkyl of which the imidazole and triazole groups may be substituted by one or two phenyls; alkyl and alkoxy groups containing from 1 to 3 carbon atoms, and their salts, XIV - The compound (X111) CH3CO-D-Cys-Leu-Ile-Thr-Arg-C! s-Ar9-TYr-NH 2 (XIII) and the compound (XIV) I-Cys-Pro-Cys-Tyr-Arg-Leu-Arg-Tyr-NH2 The-Cys-Pro-Cys-Tyr-Arg -Leu-Arg-Tyr-NH2 XV - Extracts obtained by extraction of a spongiary, Orina sp. Gray or Gellius sp., Their salts and mixtures thereof. XVI - The fermentation extracts of strains of Aspergillus, and in particular the compound (XV) (XIV) ## STR13 ## The extracts obtained by fermentation of strains of Actinomycetaceae, XVIII. from Cynara scolymus. 5. Use according to any one of the preceding claims, characterized in that said agent is present in the composition in an amount ranging from 10-8 to 10% by weight relative to the total weight of the composition. 6. Use according to any one of the preceding claims, characterized in that said agent has a specific affinity for the Y1 receptor of NPY. 20 25 7. Use according to any one of the preceding claims, characterized in that said agent is adsorbed or incorporated into particles of size ranging from 1 nm to 10 .mu.m. 8. Use according to any one of claims 1 to 7, characterized in that the composition further comprises at least one agent selected from solvents, oils, waxes, pastes, gums, fillers, materials dyes, cosmetic active ingredients, thickeners, surfactants, moisturizers, softeners, sequestering agents, fragrances, neutralizers, preservatives, antioxidants, UV filters, bactericides, odor absorbers, trace elements and their mixtures. 9. Use according to claim 8, characterized in that the cosmetic active agents are chosen from agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation, moisturizing agents, anti-pollution or anti-radical agents, soothing agents, tensors. 10. Use according to any one of claims 1 to 9, characterized in that said agent is combined in the composition with at least one makeup agent with optical effect of volume of the lips, such as goniochromatic pigments, reflective particles and their mixtures. 11. Use according to any one of claims 1 to 10, characterized in that the composition is in the form of a lipstick, a liquid gloss, a lipstick, a lip contour pencil, a lip balm. lips, a nail polish. 12. A cosmetic process for repulping and / or coloring the lips naturally, characterized in that a composition is applied to the lips comprising at least one neuropeptide Y antagonist chosen from chemical, peptide or non-peptide molecules, or extract selected from extracts obtained by extraction of a spongy Orina sp., Gray or Gellius sp., extracts of fermentations of strains of Aspergillus, extracts obtained by fermentation of strains of Actinomycetaceae and extracts obtained from Cynara scolymus. 13. Cosmetic process according to the preceding claim, characterized in that the application on the lips of the composition comprising at least one neuropeptide Y antagonist selected from chemical molecules, peptidic or non-peptide or an extract selected from extracts obtained by Extraction of Orina sp., Gray or Gellius sp., extracts of fermentations of strains of Aspergillus, extracts obtained by fermentation of Actinomycetaceae strains and extracts obtained from Cynara scolymus, is carried out beforehand. applying to said lips a composition which does not comprise an antagonist of neuropeptide Y. A lip care kit or kit comprising: a) a composition selected from a lipstick, a liquid gloss, a lipstick, a lip contour pencil, a lip balm or a lip gloss, and ) a second composition comprising, as active agent, at least one neuropeptide Y antagonist chosen from chemical, peptide or non-peptide molecules or an extract selected from extracts obtained by extracting a Spongarium Orina sp., Gray or Gellius sp. ., extracts of fermentations of strains of Aspergillus, extracts obtained by fermentation of strains of Actinomycetaceae and extracts obtained from Cynara scolymus.